var title_f15_4_15424="FAST subxiphoid effusion";
var content_f15_4_15424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Subxiphoid view with pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ultrasound image reveals a large pericardial effusion (E) seen using a subxiphoid view as part of the FAST examination.",
"    <div class=\"footnotes\">",
"     LV: left ventricle",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15424=[""].join("\n");
var outline_f15_4_15424=null;
var title_f15_4_15425="Vertebral fracture raloxifene";
var content_f15_4_15425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Reduction in vertebral fractures with raloxifene",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 653px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cumulative proportion of women with at least one incident vertebral fracture at&nbsp;four years. Women with or without prevalent vertebral fractures, and who had a baseline and any follow-up radiograph, were treated with placebo, or raloxifene 60 mg/day or 120 mg/day. A) Total study population (n = 6828). B) Women (n = 5077) who reported no use of other bone-active agents in year four. The numbers above each bar indicate the number of women in each group who had a new vertebral fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609. file://jcem.endojournals.org. Copyright &copy; 2002 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15425=[""].join("\n");
var outline_f15_4_15425=null;
var title_f15_4_15426="AIRTRAQ pediatric sizes";
var content_f15_4_15426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    AIRTRAQ pediatric sizes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Airtraq laryngoscopes come in a variety of sizes (A), including (B) infant (gray), and (C) pediatric (pink).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Airtraq LLC. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15426=[""].join("\n");
var outline_f15_4_15426=null;
var title_f15_4_15427="Septated serous cystadenoma";
var content_f15_4_15427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian serous cystadenoma with septations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound image of the left ovary showing a serous cystadenoma of the left ovary. A multiseptated (arrows) cystic structure is noted in the left adnexa. The anechoic cystic areas have no solid areas nor areas of nodularity. Ovarian tissue is seen surrounding the cystic mass (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thomas D Shipp, MD. Copyright &copy; Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15427=[""].join("\n");
var outline_f15_4_15427=null;
var title_f15_4_15428="Membranous VSD with double chambered RV";
var content_f15_4_15428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1181px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76939/Membr_VSD_doub_chamb_movie.mp4?title=Membranous+VSD+with+double+chambered+RV\" style=\"width:496px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Membranous VSD with double chambered RV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the moving clip from the subcostal parasagittal image window, the dynamic nature of the narrowing of the RVOT is highlighted by the superimposed color flow mapping. Systolic left-to-right flow from the VSD is also seen crossing the ventricular septum and entering the right ventricle caudal to the mid-chamber obstruction.",
"    <div class=\"footnotes\">",
"     PA: pulmonary artery; LVOT: left ventricular outflow tract; LA: left atrium; RV: right ventricle; IVS: intraventricular septum; thin arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15428=[""].join("\n");
var outline_f15_4_15428=null;
var title_f15_4_15429="Cervical cancer treatment; early stage cancer";
var content_f15_4_15429=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/4/15429/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15429/contributors\" id=\"au208\">",
"       Jennifer F De Los Santos, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15429/contributors\" id=\"au3965\">",
"       J Michael Straughn, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/4/15429/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15429/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/4/15429/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15429/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/4/15429?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     More than 11,000 American women develop cervical cancer each year. However, cervical cancer is a treatable condition and there is a good chance of cure if the cancer is found and treated in the early stages.",
"    </p>",
"    <p>",
"     This article discusses the diagnosis and treatment of women with early stage cervical cancer. A separate article discusses the treatment of early stage cervical cancer in women who want to become pregnant in the future. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"      \"Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4327830\">",
"     <span class=\"h1\">",
"      THE CERVIX",
"     </span>",
"    </p>",
"    <p>",
"     The uterus (womb) opens into the vagina through the cervix (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). Squamous cells make up the outer layer of the cervix. Squamous cell carcinoma of the cervix is the name for cancer that affects these cells.",
"    </p>",
"    <p>",
"     The cervix also includes glandular (also called columnar) cells, which line the opening of the cervix and the canal that leads into the uterus (the endocervical canal). These cells can also become cancerous; when they do, they are called adenocarcinomas of the cervix. Although they arise from different types of cells, squamous cell carcinoma and adenocarcinoma of the cervix are treated similarly in the early stages.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4327880\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     The most common risk factor for cervical cancer is infection with a virus called human papillomavirus (HPV). HPV is spread by direct skin-to-skin contact, including sexual intercourse, oral sex, anal sex, or any other contact involving the genital area (eg, hand to genital contact). HPV infection can also cause a noncancerous condition called condyloma (genital warts). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"      \"Patient information: Genital warts in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most HPV infections are temporary because the body's immune system effectively clears the infection. When certain types of the HPV virus persist in the body, there is a higher likelihood that the viral infection will cause cervical cell abnormalities such as dysplasia or cancer; persistent infections are believed to occur in 10 to 20 percent of women. Evidence of HPV infection can be detected in almost all cervical cancers (squamous cell carcinomas as well as adenocarcinomas). For more information about HPV testing, (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Additional risk factors for cervical cancer include cigarette smoking and a weakened immune system (caused by certain diseases, medications, or",
"     <span class=\"nowrap\">",
"      HIV/AIDS).",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Typically, cervical cancers develop slowly over a period of several years. In some women, the cancer does not cause any symptoms, while in others it causes abnormal vaginal bleeding or discharge. This can include bleeding between menstrual periods, bleeding after sex, or bleeding after menopause. This bleeding may be no more than a spot of blood.",
"    </p>",
"    <p>",
"     Abnormal bleeding can also be caused by a number of other conditions, not related to cancer. If you have abnormal vaginal bleeding, make an appointment to see your doctor or nurse.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Cervical cancer is diagnosed with a cervical biopsy. A biopsy involves removing a small piece of tissue. The biopsy is performed during an office visit using a procedure called colposcopy. The colposcope (similar to a large magnifying lens) magnifies the cervix. This allows the clinician to better see the location, extent, and degree of very small abnormalities that may not be visible with the naked eye alone. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/48/6914?source=see_link\">",
"      \"Patient information: Colposcopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The tissue obtained during the biopsy is analyzed with a microscope to see if cervical cancer cells are present. In some cases, a larger biopsy called cervical conization is needed (",
"     <a class=\"graphic graphic_figure graphicRef63427 \" href=\"UTD.htm?11/40/11906\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     If a biopsy shows cervical cancer, you should see a doctor who specializes in cancers of the female reproductive system (called a gynecologic oncologist).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER STAGING",
"     </span>",
"    </p>",
"    <p>",
"     Once cervical cancer is diagnosed, the next step is to determine its stage. Staging is a system used to describe the spread of a cancer. Cervical cancer is staged mainly based upon the results of physical examination, which includes a complete pelvic (internal) examination of the cervix, uterus, and ovaries. Other procedures may also be performed to evaluate how far the cancer has invaded within the pelvis. Patients may also be asked to undergo a chest x-ray or bone x-rays to detect whether the cancer has spread outside or distant to the pelvis. The most common sites of distant spread are the lungs and bone.",
"    </p>",
"    <p>",
"     A cervical cancer's stage is assigned based on:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The size of the cancer",
"      </li>",
"      <li>",
"       How deeply the cancer has invaded into the tissue surrounding the cervix",
"      </li>",
"      <li>",
"       If there are signs of cancer in the vagina, pelvis, or local lymph nodes (",
"       <a class=\"graphic graphic_figure graphicRef77184 \" href=\"UTD.htm?23/48/24321\">",
"        figure 3",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       If there are signs of cancer spread to other organs",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Cervical cancer stages range from stage I (cancer is in the cervix or uterus only) to stage IV (the cancer has spread to distant organs, such as the liver). In general, lower stage cancers require less treatment than higher stage cancers.",
"    </p>",
"    <p>",
"     Other imaging tests are often recommended to determine the best treatment approach, but the results do typically not change the stage. These include computed tomography (CT scan), magnetic resonance imaging (MRI),",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     positron emission tomography (PET scan).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     There are several options for treatment of early stage cervical cancer. Decisions about treatment depend on your age and health, the stage of the cancer, and you and your doctor's preferences.",
"    </p>",
"    <p>",
"     The most common treatment for early stage cervical cancers is radical hysterectomy (surgical removal of the cervix and uterus). The alternative is radiation therapy, which is usually given in combination with chemotherapy. Some patients with the earliest stage cervical cancers can be treated with cervical conization or simple hysterectomy alone. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"      \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"      \"Patient information: Abdominal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is not possible to become pregnant after having a hysterectomy or pelvic radiation therapy. In women with early stage cervical cancer, it is sometimes possible to have a less aggressive treatment, which would allow you to carry a pregnancy. These issues are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"      \"Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Radical hysterectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical hysterectomy is a surgical procedure that involves removing the uterus, cervix, and some of the vagina (",
"     <a class=\"graphic graphic_figure graphicRef78941 \" href=\"UTD.htm?31/57/32658\">",
"      figure 4",
"     </a>",
"     ). The ovaries do not necessarily have to be removed during a hysterectomy; this decision depends on your age and other factors. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link&amp;anchor=H14#H14\">",
"      \"Patient information: Abdominal hysterectomy (Beyond the Basics)\", section on 'Removal of ovaries'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The surgery is usually performed through an incision in the abdomen (",
"     <a class=\"graphic graphic_figure graphicRef57901 \" href=\"UTD.htm?37/40/38534\">",
"      figure 5",
"     </a>",
"     ). Alternately, surgery can be done through several small incisions using a laparoscope. The surgical approach depends on your surgeon's preference and other factors.",
"    </p>",
"    <p>",
"     The surgery generally takes three hours. Most women stay in the hospital for two to three days after surgery.",
"    </p>",
"    <p>",
"     If abnormal or cancerous cells are found at the margins (edges) of the tissue or lymph nodes that are removed, or if the tumor has other features that increase the risk that the cancer will come back, further (adjuvant) treatment is recommended. This generally includes both radiation therapy and chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy (RT) refers to the use of high-energy x-rays to stop the growth of the cancer. There are two ways to deliver radiation therapy: brachytherapy and external beam radiation therapy (EBRT).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Brachytherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Brachytherapy delivers radiation from a device that is temporarily placed inside the vagina. This delivers a high dose of radiation to the area where cancer cells are most likely to be found, with the hope of minimizing the effects of radiation on healthy tissues.",
"    </p>",
"    <p>",
"     There are two types of vaginal brachytherapy: low dose rate and high dose rate.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Low dose rate brachytherapy uses a device that delivers radiation through the vagina for two or three days, 24 hours per day. You stay in the hospital during this treatment.",
"      </li>",
"      <li>",
"       High dose rate brachytherapy also uses a device that delivers radiation through the vagina. However, the device is placed in the vagina for only for a few minutes at a time once a day, and treatment is generally repeated three to five times. This treatment is generally given as an outpatient, and women who get high dose rate brachytherapy do not have to stay in the hospital overnight. You can usually continue your normal daily activities during treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      External beam radiation therapy (EBRT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;With external beam radiation therapy (EBRT), the source of the radiation is outside the body, and the area to be treated (referred to as the radiation \"field\") is designed carefully to limit the amount of radiation directed at healthy tissue.",
"    </p>",
"    <p>",
"     During EBRT, your body is positioned beneath the x-ray machine in the same way every day, and the radiation field is exposed to the radiation beam for a few seconds (similar to having an x-ray) once per day, five days per week for five to six weeks. This is done as an outpatient, and you can usually continue your normal daily activities during treatment.",
"    </p>",
"    <p>",
"     Brachytherapy alone is adequate treatment for the earliest stage cervical cancers. In women with more advanced disease, EBRT is generally added to brachytherapy to decrease the chance of the cancer coming back [",
"     <a class=\"abstract\" href=\"UTD.htm?15/4/15429/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Side effects of radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Possible short term side effects of RT include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Feeling tired",
"      </li>",
"      <li>",
"       Needing to empty your bladder frequently",
"      </li>",
"      <li>",
"       Discomfort with urination",
"      </li>",
"      <li>",
"       Loose stools and feeling the need to have a bowel movement frequently",
"      </li>",
"      <li>",
"       Pubic hair falling out",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Most of these problems resolve when treatment is completed.",
"    </p>",
"    <p>",
"     Longer term side effects can include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Urine leakage",
"      </li>",
"      <li>",
"       Pain or bleeding with bowel movements",
"      </li>",
"      <li>",
"       Narrowing or scarring of the vagina, which can cause pain during sex",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you are sexually active, ask your doctor or nurse about specific things that you can do to prevent pain during sex after treatment. This might include using a vaginal dilator during and after treatment. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Sexual issues after treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women who undergo EBRT for cervical cancer are given chemotherapy during the radiation therapy (an approach termed chemoradiotherapy). Chemotherapy drugs are medicines that stop or slow the growth of cancer cells.",
"    </p>",
"    <p>",
"     Chemotherapy has the ability to enhance the damaging effect of radiation therapy on cervical cancer cells; when chemotherapy drugs are used in this manner, they are referred to as \"radiation sensitizers\". The chemotherapy is usually given in a vein (IV) once per week during the course of EBRT.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4327929\">",
"     <span class=\"h2\">",
"      Support during treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women and families affected by cervical cancer worry about their short and long term health and the risk of the cancer coming back. You might continue to worry for many years after treatment ends.",
"    </p>",
"    <p>",
"     It is important to talk openly and honestly with your family and healthcare team. Many women benefit from bringing a family member or friend to doctor visits; this person can help you to understand your options, ask important questions, take notes, and feel supported.",
"    </p>",
"    <p>",
"     A variety of support options are available, both during and after treatment, including individual counseling, support groups, and Internet-based discussion groups. A list of reputable groups is available below (see",
"     <a class=\"local\" href=\"#H17\">",
"      'Where to get more information'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4327966\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Each patient with cancer is different, and it is difficult to predict what an individual woman should expect in the future. The chances that early stage cervical cancer can be cured are good in most cases. When discussing chances of cure, it is important to remember that these numbers represent averages and do not necessarily predict what will happen to you.",
"    </p>",
"    <p>",
"     The survival rates for women with early stage cervical cancer who have standard treatment are excellent. In the earliest stages (IA, confined to the cervix, no more than 5 mm deep and 7 mm wide) at five years after diagnosis, approximately 95 percent of women are alive. This means that 5 percent of women died, although the cause of death was not necessarily related to the cancer. For slightly larger cancers (IB1, confined to the cervix, less than 4 cm), approximately 90 percent of women are alive at five years after diagnosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      CERVICAL CANCER FOLLOW UP",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;After cervical cancer treatment, periodic follow-up testing and examination are recommended. There is no established schedule of testing and follow-up visits. Based on research findings and recommendations of expert groups, this is our general approach to cervical cancer follow-up [",
"     <a class=\"abstract\" href=\"UTD.htm?15/4/15429/abstract/2-4\">",
"      2-4",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A careful physical examination every three to four months for two years, then every six months during years 3 to 5, and annually thereafter.",
"      </li>",
"      <li>",
"       Cervicovaginal cytology (Pap smear) annually.",
"      </li>",
"      <li>",
"       Annual chest x-ray for the first two to five years.",
"      </li>",
"      <li>",
"       Other tests, including blood tests, PET scans, pelvic ultrasound, intravenous pyelography, and MRI are not recommended for patients who have no symptoms that suggest a cancer recurrence.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Sexual issues after treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changes after cervical cancer treatment may include vaginal shortening, narrowing, and decreased vaginal lubrication. In addition, women who were premenopausal before treatment may become postmenopausal as a result of pelvic radiation or chemotherapy. These physical changes impact sexual satisfaction because they may lead to pain during intercourse, lack of interest in sex, difficulty having an orgasm, and decreased frequency of sexual activity.",
"    </p>",
"    <p>",
"     Using a vaginal moisturizer or lubricant during intercourse can relieve some of these bothersome symptoms. Counseling for sexual",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     psychological difficulties may also be helpful. If the vagina is severely narrowed, use of vaginal dilators may help. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"      \"Patient information: Sexual problems in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cervical cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"        www.cancer.gov/clinicaltrials/learning/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H171\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5508899\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=see_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5508936\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30436?source=see_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/48/6914?source=see_link\">",
"      Patient information: Colposcopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14730?source=see_link\">",
"      Radical hysterectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link\">",
"      Small cell neuroendocrine carcinoma of the cervix",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Gynecologic Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.thegcf.org/\">",
"      www.thegcf.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gynecologic Oncology Group",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gog.org/gynecologiccancerinformation.html\">",
"      www.gog.org/gynecologiccancerinformation.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Cervical Cancer Coalition",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ncc-online.org/\">",
"      www.ncc-online.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/4/15429/abstract/1-3,5-8\">",
"      1-3,5-8",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/4/15429?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15429/abstract/1\">",
"      Nag S, Chao C, Erickson B, et al. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15429/abstract/3\">",
"      American College of Obstetricians and Gynecologists.. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Number 35, May 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 78:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15429/abstract/4\">",
"      Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009; 114:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15429/abstract/5\">",
"      Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15429/abstract/6\">",
"      Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; :CD002225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15429/abstract/7\">",
"      Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15429/abstract/8\">",
"      Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65:169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_4_15429=[""].join("\n");
var outline_f15_4_15429=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4327830\">",
"           THE CERVIX",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4327880\">",
"           CERVICAL CANCER RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CERVICAL CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CERVICAL CANCER DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CERVICAL CANCER STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           CERVICAL CANCER TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4327966\">",
"           CERVICAL CANCER PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           CERVICAL CANCER FOLLOW UP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/40/11906\" title=\"figure 2\">",
"           Cone biopsy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/48/24321\" title=\"figure 3\">",
"           Lymph nodes female PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/57/32658\" title=\"figure 4\">",
"           Radical hysterectomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\" title=\"figure 5\">",
"           Abdominal hysterectomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_4_15430="PIP extension";
var content_f15_4_15430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60190%7EEM%2F71895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60190%7EEM%2F71895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Examination of finger PIP joint extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger PIP joint flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15430=[""].join("\n");
var outline_f15_4_15430=null;
var title_f15_4_15431="Etiologies of fever of unknown origin in adults";
var content_f15_4_15431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiologies of fever of unknown origin in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15431/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15431/contributors\">",
"     David H Bor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15431/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15431/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15431/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/4/15431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians commonly refer to a febrile illness without an initially obvious etiology or without localizing signs as fever of unknown origin (FUO). This usage is not accurate. Most febrile illnesses either resolve before a diagnosis can be made or develop distinguishing characteristics which lead to a diagnosis. FUO refers to a prolonged febrile illness without an established etiology despite intensive evaluation and diagnostic testing.",
"   </p>",
"   <p>",
"    Large case series of FUO applying this definition have been collected over a number of decades; these facilitate an approach to patients with FUO and an understanding of the changing patterns of FUO with time and newer diagnostic techniques.",
"   </p>",
"   <p>",
"    The common and uncommon entities causing FUO in adults will be reviewed here. The definitions of this condition, an approach to the adult with FUO, and the etiology of FUO in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link\">",
"     \"Approach to the adult with fever of unknown origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"     \"Etiologies of fever of unknown origin in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three general categories of illness account for the majority of \"classic\" FUO cases and have been consistent through the decades:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Connective tissue diseases (eg, vasculitis, systemic lupus erythematosus, polymyalgia rheumatica)",
"     </li>",
"     <li>",
"      Malignancies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMMON CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most prevalent causes of FUO are infection, noninfectious inflammatory diseases, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Infections and malignancies as causes of FUOs have decreased over time, while inflammatory diseases and undiagnosed fevers have increased (",
"    <a class=\"graphic graphic_table graphicRef54701 graphicRef66395 \" href=\"UTD.htm?24/27/25022\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73878 \" href=\"UTD.htm?40/21/41310\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infections and noninfectious inflammatory diseases each account for 15 to 25 percent of FUOs, while malignancies cause less than 20 percent of these fevers. The rate of no diagnosis in studies published since 1990 has varied widely from 9 to 51 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/3-8,10\">",
"     3-8,10",
"    </a>",
"    ]. The prevalence of various febrile conditions also reflects geography, subpopulations under study, host and microbial factors, and hospital and health services.",
"   </p>",
"   <p>",
"    In one of the latest published series, 73 patients from The Netherlands seen between December 2003 and July 2005 were evaluated for FUO [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/8\">",
"     8",
"    </a>",
"    ]. The following distribution of causes was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Connective tissue diseases &mdash; 22 percent",
"     </li>",
"     <li>",
"      Infection &mdash; 16 percent",
"     </li>",
"     <li>",
"      Malignancy &mdash; 7 percent",
"     </li>",
"     <li>",
"      Miscellaneous &mdash; 4 percent",
"     </li>",
"     <li>",
"      No diagnosis &mdash; 51 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most adults who remain undiagnosed after an extensive evaluation have a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the adult with fever of unknown origin\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among infections, tuberculosis and abscesses are the most common etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis (TB) is the single most common infection in most FUO series. Presentations of TB, which escape early detection, are either extrapulmonary, miliary, or occur in the lungs of patients with significant preexisting pulmonary disease, or immunodeficiency. As an example, pulmonary tuberculosis in patients with AIDS is often subtle, and the chest x-ray is normal in 15 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disseminated (miliary) TB is readily treatable, while death can occur in patients who remain untreated. Thus, a vigorous search for this disorder should be pursued.",
"   </p>",
"   <p>",
"    The PPD skin test is positive in fewer than 50 percent of patients with TB who present with an FUO, usually due to cutaneous anergy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/13\">",
"     13",
"    </a>",
"    ]. The interferon-gamma release assay also has low sensitivity for the diagnosis of active TB [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/14\">",
"     14",
"    </a>",
"    ]. Sputum samples are positive in only one-quarter of cases. Because of these difficulties, establishing the diagnosis often requires biopsy of affected nodes, bone marrow, or liver.",
"   </p>",
"   <p>",
"    Techniques for isolation of M. tuberculosis from blood include isolator cultures and polymerase chain reaction (PCR) on BACTEC blood culture bottles with evidence of early growth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Both of these methods have yielded positive results in approximately 16 days although PCR may be more sensitive and specific [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult abscesses are usually located in the abdomen or pelvis. Underlying conditions, which predispose to abscess formation, include cirrhosis, steroid or immunosuppressive medications, recent surgery, and diabetes. Abscesses arise when there has been disruption of a barrier such as the bowel wall in appendicitis, diverticulitis, or inflammatory bowel disease. The rupture often seals off spontaneously and local peritonitis is converted to an abscess by host defense mechanisms. Intraabdominal abscesses can develop in subphrenic, omental, pouch of Douglas, pelvic, and retroperitoneal locations in addition to visceral sites.",
"   </p>",
"   <p>",
"    The source of infection in these abscesses can vary with the site of abscess formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pyogenic liver abscesses usually follow biliary tract disease or abdominal suppuration such as appendicitis or diverticulitis. Amebic liver abscesses cannot be distinguished on clinical grounds from pyogenic abscesses; amebic serology is positive in more than 95 percent of cases of extraintestinal disease.",
"     </li>",
"     <li>",
"      Hematogenous seeding rather than contiguous spread accounts for the majority of splenic abscesses, which are often missed prior to autopsy; endocarditis is the most common infection currently associated with splenic abscess.",
"     </li>",
"     <li>",
"      Perinephric or renal abscesses usually arise from existing infection in the urinary tract although urine cultures may be negative or only intermittently positive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"       \"Renal and perinephric abscess\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis should be considered as a cause of FUO since localized symptoms in some sites may not be prominent. Examples include vertebral osteomyelitis and osteomyelitis of the mandible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Bacterial endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures are negative in 2 to 5 percent of patients with infective endocarditis even when the utmost care is taken in obtaining the proper number and volume of blood cultures. The frequency of negative cultures is higher in patients who have already been treated with antimicrobials, such as intravenous drug users who frequently self-administer antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Culture-negativity is particularly likely with the following organisms, which are more difficult to isolate in culture:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coxiella burnetii (Q fever) and Tropheryma whipplei occasionally cause endocarditis but will not grow using cell free media. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15255?source=see_link\">",
"       \"Q fever endocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=see_link\">",
"       \"Whipple's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brucella, Mycoplasma, Chlamydia, Histoplasma, Legionella, and Bartonella will not grow unless special media or microbiologic methods are employed.",
"     </li>",
"     <li>",
"      Haemophilus spp, Actinobacillus, Cardiobacterium, Eikenella, and Kingella, the so-called HACEK group, will not be detected unless blood cultures are incubated for 7 to 21 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The microbiology laboratory should be notified when endocarditis or other infections with such organisms are suspected since most laboratories routinely discard blood cultures when there has been no growth after seven days of incubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-culture-based diagnostic modalities can be used to increase the diagnostic yield when culture-negative endocarditis is suspected (eg, serologic assays or the polymerase chain reaction). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=see_link&amp;anchor=H8#H8\">",
"     \"Culture-negative endocarditis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral manifestations are rarely detected in subacute endocarditis presenting as FUO. Endocarditis in intravenous drug users is often right-sided, lacks murmurs, and self-administration of antimicrobials may obscure the detection of bacteremia.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography is positive in over 90 percent of cases of infective endocarditis presenting as FUO [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/13\">",
"     13",
"    </a>",
"    ]. False-positive results may be due to anatomic abnormalities or noninfective vegetations; false-negative results occur with small vegetations or those that have already embolized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, other endovascular infections (eg, mycotic aneurysms, septic thrombophlebitis) can be occult causes of fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link\">",
"     \"Suppurative (septic) thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult Still's disease in young and middle-aged adults and giant cell arteritis (GCA) in older individuals are the most common rheumatologic disorders presenting as FUO. GCA accounts for approximately 15 percent of cases of FUO in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adult Still's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult Still's disease is an inflammatory disorder characterized by quotidian (daily) fevers, arthritis, and an evanescent rash. Patients with adult Still's disease have features similar to children with systemic onset juvenile idiopathic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult Still's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of GCA should be considered in a patient over the age of 50 who complains of headache, abrupt loss of vision, symptoms of polymyalgia rheumatica (which can occur without signs of vasculitis), unexplained fever or anemia, and a high erythrocyte sedimentation rate. The manifestations of GCA, however, can vary and may be transient. Jaw claudication, if present, is helpful in suspecting the diagnosis of GCA. Temporal artery biopsy is suggested in all cases of suspected GCA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rheumatic disorders also may present as an FUO, including polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/18\">",
"     18",
"    </a>",
"    ], Takayasu's arteritis (which is common in Japan), granulomatosis with polyangiitis (Wegener&rsquo;s), and mixed cryoglobulinemia. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common malignancies to present with FUO are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphoma, especially non-Hodgkin's",
"     </li>",
"     <li>",
"      Leukemia",
"     </li>",
"     <li>",
"      Renal cell carcinoma",
"     </li>",
"     <li>",
"      Hepatocellular carcinoma or other tumors metastatic to the liver",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most frequent occult malignancies to cause fever are of reticuloendothelial origin (eg, lymphoma and leukemia). Fever is most often evident in advanced lymphomas or in those with aggressive histologic patterns. CT or MRI of the chest, abdomen, and pelvis, and bone marrow biopsy usually identifies the sites of involvement.",
"   </p>",
"   <p>",
"    Myelodysplastic syndromes occasionally present with fever and subtle evidence on blood smear of maturation arrest or dysplastic changes in one or several of the blood cell lines. Aleukemic leukemias are usually of the myeloid line. The diagnosis is made by bone marrow biopsy. Multiple myeloma has also been reported as a cause of FUO [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal cell carcinoma presents with fever in approximately 20 percent of cases. Microscopic hematuria and erythrocytosis may occur, but frequently there are no urine sediment abnormalities and the hematocrit is normal. Other adenocarcinomas also can cause fever, often but not invariably in the presence of hepatic metastases.",
"   </p>",
"   <p>",
"    Atrial myxomas are uncommon, but present with fever in approximately one-third of cases. Other findings include arthralgias, emboli, and hypergammaglobulinemia. The diagnosis is usually established by echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;One-third of hospitalized patients suffer from adverse drug reactions, including \"drug fever.\" Drugs cause fever by stimulating an allergic or idiosyncratic reaction, or by affecting thermoregulation. Eosinophilia and rash accompany drug fever in only 25 percent of cases; thus, the absence of these findings should not preclude a search for a possible offending drug [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/20\">",
"     20",
"    </a>",
"    ]. The most common drugs that cause fever include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antimicrobials (sulfonamides, penicillins,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , antimalarials)",
"     </li>",
"     <li>",
"      H1 and H2 blocking antihistamines",
"     </li>",
"     <li>",
"      Antiepileptic drugs (barbiturates and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Iodides",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (including salicylates)",
"     </li>",
"     <li>",
"      Antihypertensive drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antithyroid drugs",
"     </li>",
"     <li>",
"      Contaminants such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      that accompany injected cocaine or heroin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of drugs rarely cause fever, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and aminoglycosides.",
"   </p>",
"   <p>",
"    Drug reactions occur in as many as 24 percent of patients with AIDS, but rash and nausea are more common at presentation than fever. In two series of patients with AIDS, isolated fever occurred in 1.7 and 0 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/5,21\">",
"     5,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug fever may occur shortly after initiating a medication. However, it is not uncommon for several weeks or, in some cases, months to years to elapse prior to the start of fever.",
"   </p>",
"   <p>",
"    The diagnosis of drug fever is made by a therapeutic trial of stopping the suspected drug (with occasional rechallenge). Most patients will defervesce within 72 hours after substituting drugs, although some may not recover for weeks. Clearance of offending drug derivatives may be delayed if the derivatives become bound or haptenated on long-lived host proteins. Drugs of the same class should not be reintroduced in a therapeutic trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LESS COMMON CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the uncommon causes of FUO are listed in the following Table (",
"    <a class=\"graphic graphic_table graphicRef62509 \" href=\"UTD.htm?24/1/24605\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Factitious fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious fever is usually a manifestation of an underlying psychiatric condition that predominantly affects women and healthcare professionals. Patients with factitious fever feign illness for some secondary gain. They may also display evidence of self-mutilation and may have had multiple hospitalizations, invasive diagnostic tests (eg, cardiac catheterization), and surgery. The response to psychiatric intervention has been discouraging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=see_link\">",
"     \"Factitious disorder and Munchausen syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever elevations may be fabricated through manipulation of thermometers. Manipulated temperature elevations can be extreme, sometimes exceeding 41&ordm;C, and the fever cycles may not be accompanied by the expected patient behavior and physical signs such as chills, covering with blankets, cool extremities, sweats, warm extremities, and tachycardia. Current widespread use of electronic thermometers diminishes the opportunity to manipulate or exchange thermometers.",
"   </p>",
"   <p>",
"    Fever also can be induced by taking medications to which patients are allergic (eg, phenolphthalein), or by injecting foreign matter parenterally (eg, milk, urine, culture material, feces). The resulting illness may be associated with polymicrobial bacteremia, episodes of bacteremia caused by different pathogens, or recurrent soft tissue infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Disordered heat homeostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disordered heat homeostasis occasionally follows hypothalamic dysfunction (eg, following a massive stroke or anoxic brain injury), or abnormal heat dissipation (from skin conditions such as ichthyosis). Excess heat production may also occur from illnesses such as hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dental abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical dental abscesses are a rare cause of persistent fever that can be overlooked by the patient and physician. Among the 20 case reports in the literature, most individuals defervesced following removal of the decayed teeth, with or without antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/22\">",
"     22",
"    </a>",
"    ]. Other conditions linked to oral disease include brain abscesses, meningitis, mediastinal abscesses, and endocarditis; these are more common than dental FUO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of more obscure infections that are associated with FUO and usually have a pulmonary component include Q fever, leptospirosis, psittacosis, tularemia, and melioidosis. Other less common infections that cause FUO but do not have pulmonary manifestations include secondary syphilis, disseminated gonococcemia, chronic meningococcemia, visceral leishmaniasis, Whipple's disease, and yersiniosis. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic signs and symptoms of alcoholic hepatitis are fever, hepatomegaly, jaundice, and anorexia. Fever is typically modest (&lt;38.3&ordm;C). There are several characteristic laboratory abnormalities in alcoholic hepatitis. The most typical is serum aminotransferase elevations to less than 500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    with a disproportionate elevation of AST (SGOT) compared to ALT (SGPT); the ratio is usually greater than 2.0, a value that is rarely seen in other forms of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other noninfectious disorders may present as an FUO:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Venous thrombosis and thromboembolism, although more common presentations include dyspnea, pleuritic pain, cough, and hemoptysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematoma (eg, from trauma, rupture of an aortic aneurysm, or spontaneously in an anticoagulated patient) with subsequent inflammation. The hip, pelvis, and retroperitoneum can hide a substantial amount of blood.",
"     </li>",
"     <li>",
"      Hyperthyroidism and subacute thyroiditis occasionally cause FUO, although these conditions most frequently are diagnosed clinically.",
"     </li>",
"     <li>",
"      Other endocrine causes of fever include pheochromocytoma and adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hereditary periodic fever syndromes, such as familial Mediterranean fever (FMF), tumor necrosis factor receptor-1-associated periodic syndrome (also called TRAPS), hyper-IgD syndrome, Muckle-Wells syndrome, and familial cold autoinflammatory syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15431/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"       \"New onset urticaria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three general categories of illness account for the majority of \"classic\" FUO cases and have been consistent through the decades (",
"      <a class=\"graphic graphic_table graphicRef54701 graphicRef66395 \" href=\"UTD.htm?24/27/25022\">",
"       table 1A-B",
"      </a>",
"      ). These categories are infections, connective tissue diseases, and malignancy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among infections, tuberculosis and abscesses are the most common etiologies presenting as FUO. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic onset juvenile idiopathic arthritis (JIA, formerly called Still's disease) in younger patients, and giant cell arteritis (GCA) in older individuals are the most common rheumatologic disorders presenting as FUO. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Connective tissue diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common malignancies to present with FUO are lymphoma, especially non-Hodgkin's, leukemia, renal cell carcinoma, and hepatocellular carcinoma or other tumors metastatic to the liver. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug fever due to a variety of drugs is also a common cause of FUO. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many less common causes of FUO (",
"      <a class=\"graphic graphic_table graphicRef62509 \" href=\"UTD.htm?24/1/24605\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Less common causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/1\">",
"      Alt HL, Barker MH. Fever of unknown origin. JAMA 1930; 94:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/2\">",
"      PETERSDORF RG, BEESON PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/3\">",
"      de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore) 1997; 76:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/4\">",
"      Vanderschueren S, Knockaert D, Adriaenssens T, et al. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 2003; 163:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/5\">",
"      Miller RF, Hingorami AD, Foley NM. Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS. Int J STD AIDS 1996; 7:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/6\">",
"      Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993; 41:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/7\">",
"      Zenone T. Fever of unknown origin in adults: evaluation of 144 cases in a non-university hospital. Scand J Infect Dis 2006; 38:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/8\">",
"      Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) 2007; 86:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/9\">",
"      Horowitz HW. Fever of unknown origin or fever of too many origins? N Engl J Med 2013; 368:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/10\">",
"      Knockaert DC, Dujardin KS, Bobbaers HJ. Long-term follow-up of patients with undiagnosed fever of unknown origin. Arch Intern Med 1996; 156:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/11\">",
"      Foley NM, Miller RF. Tuberculosis and AIDS: is the white plague up and coming? J Infect 1993; 26:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/12\">",
"      Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994; 193:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/13\">",
"      Arnow PM, Flaherty JP. Fever of unknown origin. Lancet 1997; 350:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/14\">",
"      Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-&gamma; release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis 2011; 204 Suppl 4:S1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/15\">",
"      Tholcken CA, Huang S, Woods GL. Evaluation of the ESP Culture System II for recovery of mycobacteria from blood specimens collected in isolator tubes. J Clin Microbiol 1997; 35:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/16\">",
"      Smith MB, Bergmann JS, Woods GL. Detection of Mycobacterium tuberculosis in BACTEC 12B broth cultures by the Roche Amplicor PCR assay. J Clin Microbiol 1997; 35:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/17\">",
"      Molavi A. Endocarditis: recognition, management, and prophylaxis. Cardiovasc Clin 1993; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/18\">",
"      Kamimura T, Hatakeyama M, Torigoe K, et al. Muscular polyarteritis nodosa as a cause of fever of undetermined origin: a case report and review of the literature. Rheumatol Int 2005; 25:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/19\">",
"      Mueller PS, Terrell CL, Gertz MA. Fever of unknown origin caused by multiple myeloma: a report of 9 cases. Arch Intern Med 2002; 162:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/20\">",
"      Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med 1987; 106:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/21\">",
"      Harb GE, Alldredge BK, Coleman R, Jacobson MA. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1993; 6:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/22\">",
"      Siminoski K. Persistent fever due to occult dental infection: case report and review. Clin Infect Dis 1993; 16:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/23\">",
"      Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/24\">",
"      Simon HB, Daniels GH. Hormonal hyperthermia: endocrinologic causes of fever. Am J Med 1979; 66:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15431/abstract/25\">",
"      Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001; 345:1748.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2737 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15431=[""].join("\n");
var outline_f15_4_15431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMMON CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adult Still's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LESS COMMON CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Factitious fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Disordered heat homeostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dental abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2737|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/21/41310\" title=\"figure 1\">",
"      Causes of FUO over time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2737|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/24/8589\" title=\"table 1A\">",
"      Case studies of FUO I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/47/22269\" title=\"table 1B\">",
"      Case studies of FUO II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/1/24605\" title=\"table 2\">",
"      Less common causes of FUO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=related_link\">",
"      Approach to the adult with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=related_link\">",
"      Clinical manifestations and diagnosis of adult Still's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=related_link\">",
"      Culture-negative endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15255?source=related_link\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=related_link\">",
"      Renal and perinephric abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11833?source=related_link\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_4_15432="Friedreich ataxia";
var content_f15_4_15432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Friedreich ataxia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Puneet Opal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Huda Y Zoghbi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15432/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/4/15432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Friedreich ataxia is an autosomal recessive degenerative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is the most common hereditary ataxia, occurring with a frequency of approximately 1 in 50,000 in the Caucasian population. It primarily affects the central nervous system, spinal cord, and peripheral nerves, as well as the heart and pancreas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of Friedreich ataxia are caused by loss of function mutations in the frataxin gene (FXN gene), located on chromosome 9q13 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. The great majority of patients have an expanded trinucleotide (GAA) repeat in intron 1 of both alleles of the frataxin gene. The number of repeats can vary from 66 to 1700 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,5\">",
"     1,5",
"    </a>",
"    ], compared with 7 to 34 in normal alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Most patients have repeats between 600 and 1200 triplets.",
"   </p>",
"   <p>",
"    Repeat numbers between 34 and 100 seldom result in disease, but their significance is mainly determined by whether or not they are interrupted by non-GAA repeats. Interruption stabilizes the repeat against expansions in subsequent generations. On the other hand, uninterrupted repeat tracts of this size are not stable; they are considered to be premutations because they can expand to over 300 repeats in just a single generation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The repeat expansion results in reduced transcription of the gene (ie, silencing) and decreased expression of the gene product frataxin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/7\">",
"     7",
"    </a>",
"    ]. The GAA triplet repeat expansion is found only in individuals of European, North African, Middle Eastern, or Indian origin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less than 5 percent of patients with Friedreich ataxia are compound heterozygotes with the GAA repeat containing 66 to 1700 triplets on one allele and a frataxin point mutation (missense, nonsense, intronic, or exonic) in the other allele [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/3,9-13\">",
"     3,9-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that the expanded GAA triplet repeat sequences undergo further somatic expansion in an age-dependent manner, resulting in accumulations of large expansions in the dorsal root ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/14\">",
"     14",
"    </a>",
"    ]. This mechanism may explain the progression of disease in patients with Friedreich ataxia. In addition, somatic instability in one allele having a borderline number of repeats (44 to 66) may result in a repeat length of &ge;66 for that allele in some somatic cells and tissues. Thus, somatic expansion could also cause disease in compound heterozygotes who carry a GAA repeat containing 66 to 1700 triplets on the other allele [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compound heterozygotes may exhibit phenotypic variability and atypical presentations such as delayed age of onset (older than 25 years), retained or exaggerated deep tendon reflexes, and isolated spastic paraparesis without ataxia. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic heterogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic heterogeneity of Friedreich ataxia has been described but appears to be rare, as only three families have been reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the mid 1990s, two siblings with typical features of Friedreich ataxia from two families were identified, and neither had a frataxin gene mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In 2001, a second Friedreich ataxia locus (FRDA2 gene) that maps to chromosome 9p23-9p11 was reported in a large consanguineous family from Turkey with the classic Friedreich ataxia phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further confirmation of the FRDA2 variation will be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frataxin is a mitochondrial protein whose normal role includes iron-sulfur cluster biogenesis, iron chaperoning, iron detoxification, antioxidation, and possibly the regulation of iron storage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/18\">",
"     18",
"    </a>",
"    ]. It is expressed at particularly high levels in the tissues involved in Friedreich ataxia, such as the brain, heart, and pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Overexpression of frataxin increases cellular antioxidant defense through activation of glutathione peroxidase and elevation of reduced thiols [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared with healthy controls, patients with Friedreich ataxia have impairment of enzymatic antioxidants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longstanding hypothesis is that Friedreich ataxia is a result of mitochondrial accumulation of iron, which may promote injury caused by oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/23-29\">",
"     23-29",
"    </a>",
"    ]. In support of the oxidative stress hypothesis, it has been shown that mutated frataxin is associated with deficient activity of the iron-sulphur (Fe-S) respiratory enzymes, deficient production of aconitase (an iron-sulfur protein involved in iron homeostasis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/30\">",
"     30",
"    </a>",
"    ], and failure of induction of superoxide dismutase and of the iron import machinery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, patients with Friedreich ataxia exhibit elevated levels of oxidative stress markers, including elevated urinary concentrations of 8-hydroxy-2'deoxyguanosine (8OH2'dG) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/23\">",
"     23",
"    </a>",
"    ] and elevated plasma concentrations of malondialdehyde (MDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homozygous deletions in the mouse cause embryonic lethality a few days after implantation, demonstrating an important role for frataxin during early development [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/33\">",
"     33",
"    </a>",
"    ]. The milder phenotype in humans is presumably caused by residual frataxin expression associated with the expansion mutations. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetics'",
"    </a>",
"    above.) Mutant mice with frataxin-deficient",
"    <span class=\"nowrap\">",
"     neuron/cardiac",
"    </span>",
"    muscle and frataxin-deficient striated muscle reproduce important features of the human disease, including cardiomyopathy, sensory neuropathy, deficient aconitase and respiratory chain complex activity, and intramitochondrial iron accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternate but less widely endorsed hypothesis holds that Friedreich ataxia is not associated with oxidative damage. In support of this hypothesis, there is evidence that iron accumulation occurs after the onset of pathology and late after the inactivation of the iron-sulphur (Fe-S) containing enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, there is conflicting experimental evidence regarding the importance of oxidative stress in the pathophysiology of Friedreich ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestations of Friedreich ataxia are neurologic dysfunction, cardiomyopathy, and diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/37\">",
"     37",
"    </a>",
"    ]. A 1981 report by Harding of 115 patients from 90 families established clinical criteria for the disorder: the main criteria were autosomal recessive inheritance, onset before age 25, ataxia of all four limbs, absence of lower limb reflexes, and presence of pyramidal signs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/2\">",
"     2",
"    </a>",
"    ]. However, later reports have shown that the disease presentation is more variable, with some patients having a later disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]. In a series of 187 patients, 40 percent had no affected relatives, 10 percent had a later onset (between 26 and 51 years of age), and 7 percent had retained lower limb reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the disease is progressive, the full clinical picture may not be seen until several years after presentation. As a result, early diagnosis may be difficult, particularly in patients without a positive family history [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manifestations vary in part with the number of GAA expansions. Larger GAA expansions, particularly on the smaller allele, correlate with earlier age at onset, shorter times to loss of ambulation, a greater frequency of cardiomyopathy, and loss of reflexes in the upper limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. Patients with early onset cerebellar ataxia and retained reflexes tend to have smaller repeats [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"     1",
"    </a>",
"    ]. True heterozygotes (eg, first-degree relatives) have no neurologic or cardiac abnormalities that can be ascribed to Friedreich ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of neurologic abnormalities are associated with Friedreich ataxia. Almost all patients present with ataxia of all four limbs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive ataxia of all four limbs and gait caused by cerebellar dysfunction often is present by the time the individual reaches five years of age, but it may be seen earlier. The mean time to use of a wheelchair ranges from 11 to 25 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,2,40\">",
"       1,2,40",
"      </a>",
"      ]. Cerebellar dysarthria is a common feature.",
"     </li>",
"     <li>",
"      Optic atrophy and swallowing dysfunction reflect optic pathway and brainstem involvement. Optic nerve abnormalities are seen on visual-evoked responses in up to 64 percent of patients, but only 5 to 15 percent have clinically significant optic nerve dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=see_link&amp;anchor=H26#H26\">",
"       \"Congenital anomalies and acquired abnormalities of the optic nerve\", section on 'Atrophy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pyramidal tract disease leads to pyramidal weakness and extensor plantar reflexes.",
"     </li>",
"     <li>",
"      Early loss of position and vibration sense occurs, reflecting posterior column spinal cord dysfunction, as well as dorsal root and peripheral, primarily sensory, axonal neuropathy. In turn, loss of position and vibration sense exacerbates the cerebellar ataxia. Pain and temperature sensation are retained. In almost all patients, deep tendon reflexes eventually are lost [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"       1",
"      </a>",
"      ], but they may be retained for an extended period of time in younger children [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/41\">",
"       41",
"      </a>",
"      ]. Patients with late-onset (after age 25) Friedreich ataxia are more likely to have retained reflexes, lower limb spasticity, and absence of cardiomyopathy than patients who have earlier onset disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Nerve conduction studies reflect an axonal sensory neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/43\">",
"       43",
"      </a>",
"      ]. Motor conduction velocities are only mildly slowed, and somatosensory and auditory evoked potentials are abnormal. Nerve biopsy reveals a loss of large myelinated sensory nerve fibers, and secondary axonal degeneration is seen in the later stages of the disease.",
"     </li>",
"     <li>",
"      Involvement of the autonomic nervous system typically causes bladder dysfunction.",
"     </li>",
"     <li>",
"      Distal muscle atrophy from a motor neuropathy results in pes cavus, hammer toes, and atrophy of the intrinsic small muscles of the hand. Kyphoscoliosis is common and can precede the neurologic symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5029783\">",
"    <span class=\"h3\">",
"     Neuropathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuropathologic changes in Friedreich ataxia include degeneration of the posterior columns and the spinocerebellar tracts of the spinal cord and loss of the larger sensory cells of the dorsal root ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic and echocardiographic abnormalities are characteristic of the usually hypertrophic cardiomyopathy of Friedreich ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The main clinical manifestations are arrhythmia and heart failure, which are a frequent cause of death. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In one report of 75 patients, 95 percent had electrocardiographic, vectorcardiographic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    echocardiographic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/45\">",
"     45",
"    </a>",
"    ]. Electrocardiographic findings included ST-T wave abnormalities in 79 percent, right axis deviation in 40 percent, short PR interval in 24 percent, abnormal R wave in lead V1 in 20 percent, abnormal inferolateral Q waves in 14 percent, and left ventricular hypertrophy in 16 percent.",
"   </p>",
"   <p>",
"    Abnormalities detected by echocardiography or cardiac MRI have been reported in up to two-thirds of patients with Friedreich ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,47-50\">",
"     1,47-50",
"    </a>",
"    ]. Affected patients tend to have longer GAA repeat alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1,51\">",
"     1,51",
"    </a>",
"    ]. Three types of disease can occur: concentric left ventricular hypertrophy, asymmetric septal hypertrophy, and globally decreased left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/45\">",
"     45",
"    </a>",
"    ]. The severity of cardiomyopathy does not appear to correlate with neurologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic findings include cardiomyocyte hypertrophy, fatty degeneration with diffuse interstitial fibrosis, and eosinophilic and lymphocytic infiltrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt diabetes mellitus or impaired glucose tolerance occurs in approximately one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"     1",
"    </a>",
"    ]. Diabetes appears to cluster within sibships, with a greater risk if an affected sibling is diabetic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/2\">",
"     2",
"    </a>",
"    ]. Insulin resistance and, to a lesser degree, impaired insulin release account for the alteration in glucose metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Insulin usually is required, but some patients can be controlled with oral hypoglycemic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Friedreich ataxia is based upon clinical findings but can be confirmed by genetic testing. Genetic testing should be performed in all patients with autosomal recessive ataxia, evidence of a sensory and motor axonal neuropathy on electrophysiologic testing, and electrocardiographic abnormalities indicative of cardiac involvement. Magnetic resonance imaging typically reveals spinal cord and, in some cases, cerebellar atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the full clinical picture of Friedreich ataxia may not be seen until several years after presentation. As a result, early clinical diagnosis may be difficult, particularly in patients without a positive family history [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two disorders that may be confused with Friedreich ataxia in this setting are ataxia-telangiectasia and an autosomal dominant disorder, the Roussy-Levy variant of hereditary motor and sensory neuropathy type 1 that can present with areflexia and ataxia; the peripheral neuropathy is characterized by dysmyelination rather than the axonal neuropathy seen in Friedreich ataxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other autosomal recessive ataxias are rare, but they can occur at higher rates in specific areas because of consanguineous marriages. Included in this group are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive spastic ataxia of Charlevoix-Saguenay, named after the region in Quebec where it was first described [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infantile onset spinocerebellar ataxia, which occurs in the North Karelia province of Finland [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/56\">",
"       56",
"      </a>",
"      ]. It is characterized by early onset ataxia with ophthalmoplegia and hearing loss. In addition, affected infants have EEG abnormalities and seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with typical symptoms of Friedreich ataxia do not have frataxin (FXN) gene mutations and furthermore have no other known neurologic or genetic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/17,57,58\">",
"     17,57,58",
"    </a>",
"    ]. As an example, in a study from Mexico, 16 of 30 patients (53 percent) with Friedreich ataxia phenotype did not have FXN mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/59\">",
"     59",
"    </a>",
"    ]. Genetic heterogeneity is one possible explanation that may account for some of these patients. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetic heterogeneity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, severity of disease and rate of progression are variable, with more severe disease being associated with a higher number of GAA repeats [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients die between the ages of 30 and 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/40,60\">",
"     40,60",
"    </a>",
"    ], but those with late onset disease clearly do better [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"     1",
"    </a>",
"    ]. The major cause of death is cardiac dysfunction, typically congestive heart failure or arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/61\">",
"     61",
"    </a>",
"    ]. Less often, death occurs from noncardiac causes, such as pneumonia due to bulbar dysfunction with inability to protect the airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with Friedreich ataxia often requires a team of special services that includes neurology, physical medicine, cardiology, and endocrinology. An occupational and physical therapy program should be initiated early and modified over time to address the progressive loss of balance and fine motor control; adaptive devices to assist in ambulation and activities of daily living eventually will be needed.",
"   </p>",
"   <p>",
"    Periodic evaluation of cardiac function, arrhythmia, and cardiomyopathy is required. Some experts suggest that the initial evaluation include both echocardiography and cardiac MRI, followed by periodic echocardiography during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/49\">",
"     49",
"    </a>",
"    ]. Although there is no specific treatment for Friedreich ataxia-related cardiomyopathy, conventional drugs and device implantation can be used to manage heart failure and arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, patients should be evaluated periodically for the development of diabetes. However, because of resistance to insulin, the glucose tolerance curve may be abnormal without clinical diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic counseling and psychologic counseling to aid in coping with a chronic progressive disorder also are important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific disease-modifying therapy for Friedreich ataxia. One theory holds that Friedreich ataxia may be result of mitochondrial accumulation of iron, which may promote injury caused by oxidative stress. The administration of antioxidants such as idebenone (a free radical scavenger), coenzyme Q10, or vitamin E can decrease markers of oxidative injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/23,63,64\">",
"     23,63,64",
"    </a>",
"    ], but whether such a change is clinically important remains to be proven.",
"   </p>",
"   <p>",
"    Research efforts to elucidate the mechanism of gene silencing of the expanded FXN gene may lead to therapeutic targets [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/65\">",
"     65",
"    </a>",
"    ]. There is evidence that the expansion causes the gene to become transcriptionally silent because of changes in histones, around which DNA is coiled into chromatin. These changes include decreases in acetylation. Thus, histone deacetylase inhibitors are a promising avenue of future therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Idebenone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, there is no evidence that idebenone treatment improves neurologic function in patients with Friedreich ataxia. There is conflicting evidence regarding whether idebenone reduces left ventricular mass in patients with Friedreich ataxia and cardiac hypertrophy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review updated in 2012 identified only one randomized controlled trial with treatment duration of at least 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/68\">",
"       68",
"      </a>",
"      ]. In the trial, 29 patients with Friedreich ataxia received either idebenone (5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/69\">",
"       69",
"      </a>",
"      ]. Idebenone did not improve neurologic function, but did reduce interventricular septal thickness and left ventricular mass.",
"     </li>",
"     <li>",
"      In a six month double-blind randomized trial of 48 children (ages 9 to 17) with Friedreich ataxia, the primary outcome measure, change from baseline in a marker of oxidative stress (urinary 8-hydroxy-2'-deoxyguanosine), was not significantly different with idebenone treatment compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/70\">",
"       70",
"      </a>",
"      ]. Furthermore, there was no statistically significant improvement with idebenone treatment overall in secondary outcomes assessing function.",
"     </li>",
"     <li>",
"      In another six-month double-blind randomized trial of 70 ambulatory children (ages 8 to 18) with Friedreich ataxia, idebenone treatment did not significantly affect neurologic function compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/71\">",
"       71",
"      </a>",
"      ]. Furthermore, idebenone did not improve left ventricular hypertrophy or improve cardiac function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective, open trial evaluated idebenone (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) in 38 patients with cardiac hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/73\">",
"       73",
"      </a>",
"      ]. After six months of therapy, left ventricular mass decreased by more than 20 percent in approximately one-half of the patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since idebenone is without serious side effects, some investigators believe that current data provide supportive evidence for using it continuously (5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) in patients with Friedreich ataxia at the onset of cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Iron chelation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron chelation is another possible treatment approach, but has generally been avoided because Friedreich ataxia is associated with normal or mildly reduced levels of plasma iron, despite iron accumulation in mitochondria and specific brain regions. In a small open-label study of 13 adolescent and young adult patients with Friedreich ataxia on idebenone therapy who had no overt cardiomyopathy, treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    (20 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses) for up to six months in nine patients was associated with subjective improvement in gait, and modest objective improvement in symptoms of ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/74\">",
"     74",
"    </a>",
"    ]. Four patients withdrew from the study, in one case because of reversible agranulocytosis.",
"   </p>",
"   <p>",
"    The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    has not been established, and fatal cases of agranulocytosis have been reported with this agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link&amp;anchor=H10#H10\">",
"     \"Chelation therapy for iron overload states\", section on 'Deferiprone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the treatment of Friedreich ataxia outside of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5583851\">",
"    <span class=\"h2\">",
"     Pregnancy implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, the available evidence suggests that women with Friedreich ataxia are not at high risk for complications of pregnancy or worsening of disease symptoms during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. One of the largest studies retrospectively reviewed 31 women with Friedreich ataxia from the US who had 65 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15432/abstract/76\">",
"     76",
"    </a>",
"    ]. Spontaneous abortion occurred in 14 percent, a rate lower than the estimated national incidence. Rates of preterm birth (13 percent) and preeclampsia (4 percent) were similar to the incidence of these conditions in the general population. Delivery was vaginal in 78 percent of cases. Newborns were discharged to home in 95 percent of cases. The percentage of women reporting that pregnancy made the symptoms of Friedreich ataxia worse, unchanged, or improved (36, 36, and 29 percent, respectively) was similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/57/3986?source=see_link\">",
"       \"Patient information: Friedreich ataxia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5029725\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Friedreich ataxia is an autosomal recessive degenerative disorder that primarily affects the central nervous system, spinal cord, peripheral nerves, heart, and pancreas.",
"     </li>",
"     <li>",
"      The majority of patients with Friedreich ataxia have an expanded trinucleotide (GAA) repeat in intron 1 of both alleles of the frataxin gene. The number of repeats can vary from 66 to 1700, compared with 7 to 34 in normal alleles. The repeat expansion results in reduced transcription of the gene (ie, silencing) and decreased expression of the gene product frataxin. The GAA triplet repeat expansion is found only in individuals of European, North African, Middle Eastern, or Indian origin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical manifestations of Friedreich ataxia are neurologic dysfunction, cardiomyopathy, and diabetes mellitus. Almost all patients present with limb and gait ataxia. Additional neurologic manifestations can include optic atrophy, swallowing dysfunction, upper motor neuron weakness, loss of position and vibration sense, and peripheral neuropathy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Friedreich ataxia is based upon clinical findings and should be confirmed by genetic testing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease severity and rate of progression are variable in Friedreich ataxia, with more severe disease being associated with a higher number of GAA repeats. Most patients die between the ages of 30 and 40. The major causes of death are complications related to the cardiomyopathy and bulbar dysfunction. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific disease-modifying therapy for Friedreich ataxia. The management of patients with this disorder requires a multidisciplinary team of special services. Periodic evaluation of cardiac function is required. Similarly, patients should be evaluated periodically for the development of clinical diabetes. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/1\">",
"      D&uuml;rr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996; 335:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/2\">",
"      Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981; 104:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/3\">",
"      Campuzano V, Montermini L, Molt&ograve; MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996; 271:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/4\">",
"      Carvajal JJ, Pook MA, dos Santos M, et al. The Friedreich's ataxia gene encodes a novel phosphatidylinositol-4- phosphate 5-kinase. Nat Genet 1996; 14:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/5\">",
"      Epplen C, Epplen JT, Frank G, et al. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet 1997; 99:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/6\">",
"      Coss&eacute;e M, Schmitt M, Campuzano V, et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A 1997; 94:7452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/7\">",
"      Saveliev A, Everett C, Sharpe T, et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 2003; 422:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/8\">",
"      Labuda M, Labuda D, Miranda C, et al. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology 2000; 54:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/9\">",
"      Bidichandani SI, Ashizawa T, Patel PI. Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am J Hum Genet 1997; 60:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/10\">",
"      Bartolo C, Mendell JR, Prior TW. Identification of a missense mutation in a Friedreich's ataxia patient: implications for diagnosis and carrier studies. Am J Med Genet 1998; 79:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/11\">",
"      Coss&eacute;e M, D&uuml;rr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999; 45:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/12\">",
"      McCormack ML, Guttmann RP, Schumann M, et al. Frataxin point mutations in two patients with Friedreich's ataxia and unusual clinical features. J Neurol Neurosurg Psychiatry 2000; 68:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/13\">",
"      Anheim M, Mariani LL, Calvas P, et al. Exonic Deletions of FXN and Early-Onset Friedreich Ataxia. Arch Neurol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/14\">",
"      De Biase I, Rasmussen A, Endres D, et al. Progressive GAA expansions in dorsal root ganglia of Friedreich's ataxia patients. Ann Neurol 2007; 61:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/15\">",
"      Sharma R, De Biase I, G&oacute;mez M, et al. Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann Neurol 2004; 56:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/16\">",
"      Kostrzewa M, Klockgether T, Damian MS, M&uuml;ller U. Locus heterogeneity in Friedreich ataxia. Neurogenetics 1997; 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/17\">",
"      Christodoulou K, Deymeer F, Serdaro��lu P, et al. Mapping of the second Friedreich's ataxia (FRDA2) locus to chromosome 9p23-p11: evidence for further locus heterogeneity. Neurogenetics 2001; 3:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/18\">",
"      Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011; 303:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/19\">",
"      Koutnikova H, Campuzano V, Foury F, et al. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet 1997; 16:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/20\">",
"      Puccio H, Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 2000; 9:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/21\">",
"      Shoichet SA, B&auml;umer AT, Stamenkovic D, et al. Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro. Hum Mol Genet 2002; 11:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/22\">",
"      Tozzi G, Nuccetelli M, Lo Bello M, et al. Antioxidant enzymes in blood of patients with Friedreich's ataxia. Arch Dis Child 2002; 86:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/23\">",
"      Schulz JB, Dehmer T, Sch&ouml;ls L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000; 55:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/24\">",
"      Sherer T, Greenamyre JT. A therapeutic target and biomarker in Friedreich's ataxia. Neurology 2000; 55:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/25\">",
"      Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997; 6:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/26\">",
"      Priller J, Scherzer CR, Faber PW, et al. Frataxin gene of Friedreich's ataxia is targeted to mitochondria. Ann Neurol 1997; 42:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/27\">",
"      Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997; 276:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/28\">",
"      Tan G, Chen LS, Lonnerdal B, et al. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum Mol Genet 2001; 10:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/29\">",
"      Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/30\">",
"      R&ouml;tig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997; 17:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/31\">",
"      Chantrel-Groussard K, Geromel V, Puccio H, et al. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet 2001; 10:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/32\">",
"      Emond M, Lepage G, Vanasse M, Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 2000; 55:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/33\">",
"      Coss&eacute;e M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000; 9:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/34\">",
"      Puccio H, Simon D, Coss&eacute;e M, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/35\">",
"      Seznec H, Simon D, Monassier L, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 2004; 13:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/36\">",
"      Seznec H, Simon D, Bouton C, et al. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet 2005; 14:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/37\">",
"      Delatycki MB, Corben LA. Clinical features of friedreich ataxia. J Child Neurol 2012; 27:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/38\">",
"      Bidichandani SI, Garcia CA, Patel PI, Dimachkie MM. Very late-onset Friedreich ataxia despite large GAA triplet repeat expansions. Arch Neurol 2000; 57:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/39\">",
"      Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996; 59:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/40\">",
"      De Michele G, Perrone F, Filla A, et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients. Neurology 1996; 47:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/41\">",
"      Salih MA, Ahlsten G, St&aring;lberg E, et al. Friedreich's ataxia in 13 children: presentation and evolution with neurophysiologic, electrocardiographic, and echocardiographic features. J Child Neurol 1990; 5:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/42\">",
"      Bhidayasiri R, Perlman SL, Pulst SM, Geschwind DH. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch Neurol 2005; 62:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/43\">",
"      Claus D, Harding AE, Hess CW, et al. Central motor conduction in degenerative ataxic disorders: a magnetic stimulation study. J Neurol Neurosurg Psychiatry 1988; 51:790.",
"     </a>",
"    </li>",
"    <li>",
"     Greenfield JG. The spinocerebellar degenerations, Springfield 1954.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/45\">",
"      Child JS, Perloff JK, Bach PM, et al. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. J Am Coll Cardiol 1986; 7:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/46\">",
"      Payne RM, Wagner GR. Cardiomyopathy in friedreich ataxia: clinical findings and research. J Child Neurol 2012; 27:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/47\">",
"      Morvan D, Komajda M, Doan LD, et al. Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. Eur Heart J 1992; 13:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/48\">",
"      Kipps A, Alexander M, Colan SD, et al. The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood. Pediatr Cardiol 2009; 30:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/49\">",
"      Weidemann F, Rummey C, Bijnens B, et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 2012; 125:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/50\">",
"      Meyer C, Schmid G, G&ouml;rlitz S, et al. Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI. Mov Disord 2007; 22:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/51\">",
"      Bit-Avragim N, Perrot A, Sch&ouml;ls L, et al. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. J Mol Med (Berl) 2001; 78:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/52\">",
"      Finocchiaro G, Baio G, Micossi P, et al. Glucose metabolism alterations in Friedreich's ataxia. Neurology 1988; 38:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/53\">",
"      Khan RJ, Andermann E, Fantus IG. Glucose intolerance in Friedreich's ataxia: association with insulin resistance and decreased insulin binding. Metabolism 1986; 35:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/54\">",
"      W&uuml;llner U, Klockgether T, Petersen D, et al. Magnetic resonance imaging in hereditary and idiopathic ataxia. Neurology 1993; 43:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/55\">",
"      Engert JC, B&eacute;rub&eacute; P, Mercier J, et al. ARSACS, a spastic ataxia common in northeastern Qu&eacute;bec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 2000; 24:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/56\">",
"      Nikali K, Isosomppi J, L&ouml;nnqvist T, et al. Toward cloning of a novel ataxia gene: refined assignment and physical map of the IOSCA locus (SCA8) on 10q24. Genomics 1997; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/57\">",
"      Sch&ouml;ls L, Amoiridis G, Przuntek H, et al. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 1997; 120 ( Pt 12):2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/58\">",
"      Filla A, De Michele G, Coppola G, et al. Accuracy of clinical diagnostic criteria for Friedreich's ataxia. Mov Disord 2000; 15:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/59\">",
"      Rasmussen A, G&oacute;mez M, Alonso E, Bidichandani SI. Clinical heterogeneity of recessive ataxia in the Mexican population. J Neurol Neurosurg Psychiatry 2006; 77:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/60\">",
"      Hewer RL. Study of fatal cases of Friedreich's ataxia. Br Med J 1968; 3:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/61\">",
"      Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci 2011; 307:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/62\">",
"      Jensen MK, Bundgaard H. Cardiomyopathy in Friedreich ataxia: exemplifying the challenges faced by cardiologists in the management of rare diseases. Circulation 2012; 125:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/63\">",
"      Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001; 49:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/64\">",
"      Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005; 62:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/65\">",
"      Pandolfo M. Friedreich ataxia. Arch Neurol 2008; 65:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/66\">",
"      Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/67\">",
"      Soragni E, Xu C, Plasterer HL, et al. Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for friedreich ataxia. J Child Neurol 2012; 27:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/68\">",
"      Kearney M, Orrell RW, Fahey M, Pandolfo M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev 2012; 4:CD007791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/69\">",
"      Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/70\">",
"      Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007; 6:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/71\">",
"      Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 2010; 67:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/72\">",
"      Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 2011; 161:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/73\">",
"      Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002; 87:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/74\">",
"      Boddaert N, Le Quan Sang KH, R&ouml;tig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007; 110:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/75\">",
"      MacKenzie WE. Pregnancy in women with Friedreich's ataxia. Br Med J (Clin Res Ed) 1986; 293:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15432/abstract/76\">",
"      Friedman LS, Paulsen EK, Schadt KA, et al. Pregnancy with Friedreich ataxia: a retrospective review of medical risks and psychosocial implications. Am J Obstet Gynecol 2010; 203:224.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6224 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15432=[""].join("\n");
var outline_f15_4_15432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5029725\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic heterogeneity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5029783\">",
"      - Neuropathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Idebenone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Iron chelation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5583851\">",
"      Pregnancy implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5029725\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/57/3986?source=related_link\">",
"      Patient information: Friedreich ataxia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_4_15433="Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings";
var content_f15_4_15433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15433/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15433/contributors\">",
"     Brenna Anderson, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15433/contributors\">",
"     Susan Cu-Uvin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15433/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/4/15433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/4/15433/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/4/15433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10063254\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive medical care of the HIV-infected pregnant female is associated with favorable maternal health outcomes and low rates of perinatal HIV transmission.",
"   </p>",
"   <p>",
"    This topic will review elements of prenatal care and counseling for the HIV-infected female. In 2012, the Department of Health and Human Services published updated guidelines on the evaluation and management of HIV-infected pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/1\">",
"     1",
"    </a>",
"    ]. Our recommendations below are largely consistent with these guidelines.",
"   </p>",
"   <p>",
"    The use of antiretroviral (ARV) medications during pregnancy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7447182\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history and physical examination should be performed in the HIV-infected pregnant woman to see if there are health concerns in the mother, which may also affect the well-being of the fetus. Patients should be interviewed about any history of opportunistic infections, tuberculosis, sexually transmitted diseases (STDs), medication use (including over the counter drugs), immunization status, or substance abuse issues. Immunosuppressed women who report fevers and weight loss may have an underlying opportunistic infection, which may compromise maternal and fetal health (eg, tuberculosis).",
"   </p>",
"   <p>",
"    The physical examination should be focused on assessing any signs of advanced HIV infection (eg, thrush or evidence of wasting) or signs of concomitant STDs (eg, genital ulcers or vaginal discharge). Since many HIV-infected patients are also at risk for viral hepatitis, a careful examination for stigmata of advanced liver disease (eg, hepatomegaly, splenomegaly, spider angiomata) is also indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10063269\">",
"    <span class=\"h1\">",
"     GENERAL COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal care providers should address potentially modifiable behaviors, which have been associated with an increased risk of HIV perinatal transmission, such as cigarette smoking, illicit drug use (eg, cocaine, heroin), and unprotected intercourse with multiple partners [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. Some of these risk factors are also associated with low birth weight. However, most of these studies were conducted prior to the era of potent antiretroviral therapy (ART) so the true magnitude of effect is unclear.",
"   </p>",
"   <p>",
"    Women should be counseled regarding the harmful effects of alcohol or cocaine use on fetal development. Patients should also be counseled to discontinue cigarette smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"     \"Smoking and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be advised to use condoms with sexual activity, since STDs can lead to preterm delivery and teratogenicity (eg, congenital syphilis). Providers should evaluate for evidence of sexually transmitted infections as part of routine antenatal care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10063283\">",
"    <span class=\"h1\">",
"     DETERMINATION OF GESTATIONAL AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound imaging is commonly used to estimate gestational age and thereby calculate the expected date of delivery (EDD). Several studies have demonstrated that ultrasound estimation during the first half of pregnancy is superior to estimating the delivery date based on the last menstrual period or physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accurate determination of fetal gestational age is particularly important among pregnant women with HIV infection, since early delivery may be necessary to decrease the risk of perinatal HIV transmission. Delivery by pre-labor cesarean section is recommended at 38 weeks gestation in the event of incomplete viral suppression (&ge;1000",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    Because of the potential need for an early, scheduled cesarean delivery with the attendant risk of fetal pulmonary immaturity, a first trimester ultrasound should be performed to ensure accurate pregnancy dating [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10063311\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7447723\">",
"    <span class=\"h2\">",
"     Hematocrit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal anemia has been associated with an increased risk of both adverse pregnancy outcomes as well as mother-to-child transmission (MTCT) of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/12\">",
"     12",
"    </a>",
"    ]. Correction of potential underlying causes, such as iron deficiency, is important to prevent anemia-related complications of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10063319\">",
"    <span class=\"h2\">",
"     Interpretation of CD4+ T cell counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD4 cell count should be assessed at the initial visit and at least every three months during pregnancy. For patients who have been on antiretroviral therapy (ART) for more than two to three years, have consistent viral suppression, and are clinically stable and adherent, CD4 cell count monitoring may be done every six months.",
"   </p>",
"   <p>",
"    Pregnancy itself is associated with a decline in absolute CD4 count number, which may be related to increased plasma blood volume; however, there is usually no effect on the CD4 cell percentage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Therefore, some clinicians prefer to monitor the CD4 cell percentage during pregnancy; however, treatment recommendations remain predicated upon absolute CD4 cell count numbers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H2622983#H2622983\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'The clinical benefit of ART varies by baseline CD4 cell count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decisions about the initiation of ART and prophylaxis for opportunistic infections are based on the absolute CD4 cell count. The CD4 cell criteria for initiation of ART or prophylaxis for pneumocystis, toxoplasmosis, or Mycobacterium avium complex are the same as in nonpregnant HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10063326\">",
"    <span class=\"h2\">",
"     Viral load measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma HIV RNA is monitored frequently during pregnancy to confirm attainment and maintenance of viral suppression. As in nonpregnant adults, patients should exhibit at least one log decline in plasma viremia by a month after initiation of therapy. Complete viral suppression should be achieved within 16 to 24 weeks after initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Close monitoring is desired to confirm the effectiveness of the patient&rsquo;s antiretroviral (ARV) drug regimen since higher levels of HIV RNA are associated with increased risk of perinatal transmission of HIV infection. HIV RNA levels are generally monitored at entry into care, at the time of ARV initiation, two to four weeks after initiation (or changing) of therapy, monthly until complete viral suppression and then at least every three months for the remainder of the pregnancy.",
"   </p>",
"   <p>",
"    In addition, plasma viral load should be assessed at 34 to 36 weeks gestation in order to aid in the decision regarding mode and timing of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/1\">",
"     1",
"    </a>",
"    ]. If the viral load is detectable, resistance testing and assessment of adherence is advised. If the viral load is &gt;1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    near term gestation, the patient should be counseled regarding the benefits of scheduled cesarean section at 38 weeks gestation for the prevention of perinatal transmission. (See",
"    <a class=\"local\" href=\"#H86989343\">",
"     'Mode of delivery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The relationship between HIV RNA levels and risk of perinatal transmission is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10063333\">",
"    <span class=\"h2\">",
"     Drug resistance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV ARV drug resistance testing should be performed prior to starting or modifying ARV drug regimens in all pregnant women whose HIV RNA levels are above the threshold for resistance testing (ie, &gt;500 to 1000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because viral load is associated with the risk of perinatal transmission in women who present late in pregnancy, an empiric ARV regimen should be initiated promptly without waiting for the results of resistance testing, to optimize prevention of perinatal transmission. Once test results are available, the ARV regimen can be adjusted as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8632998\">",
"    <span class=\"h2\">",
"     Testing for viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant, HIV-infected women should be screened for both hepatitis B and hepatitis C virus infections since coinfection is common in HIV-infected patients due to shared routes of transmission (eg, injection drug use). Testing for hepatitis B infection includes hepatitis B surface antigen and antibodies to core and surface antigens (ie, anti-HB core and anti-HBs). Testing for hepatitis C infection includes serologic testing; patients with advanced HIV infection (CD4 cell count &lt;100 cells) and risk factors for HCV (eg, injection drug use history) should also have HCV RNA testing since antibody testing can be falsely negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    HIV-infected women without evidence of Hepatitis B infection (ie, nonreactive anti-HB core and anti-HBs results) should begin an HBV immunization series, since the recombinant vaccine is safe to give during pregnancy. HIV-infected women with evidence of chronic hepatitis B infection will need consultation with a specialist knowledgeable in both liver and HIV disease. Certain antiretroviral (ARV) medications have dual activity against HIV and hepatitis B viruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-infected women without evidence of HCV infection should be counseled regarding avoidance of HCV acquisition (eg, abstinence from injection drug use; avoidance of unprotected intercourse with an HCV-seropositive partner). Acute infection with HCV during pregnancy is problematic because interferon alpha and pegylated interferon alfa2a are not recommended and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is contraindicated during pregnancy. Also, theoretically, there is an increased risk of HCV transmission to the infant due to the high levels of viremia that are observed during early infection.",
"   </p>",
"   <p>",
"    Vertical transmission of HCV appears to be facilitated by HIV-coinfection, compared with HIV-seronegative patients. A meta-analysis of 10 studies demonstrated that maternal coinfection increases the odds of vertical HCV transmission by approximately 90 percent (odds ratio, 1.9; 95% CI 1.4-2.7) compared with maternal HCV infection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/16\">",
"     16",
"    </a>",
"    ]. There are currently no differences in general management principles (eg, the timing or mode of delivery) based on HCV coinfection in the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448597\">",
"    <span class=\"h2\">",
"     Testing for tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients infected with HIV are at high risk of developing active disease after infection with Mycobacterium tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. For this reason, all persons should be tested for latent tuberculosis infection after HIV is diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link&amp;anchor=H2#H2\">",
"     \"Tuberculosis in pregnancy\", section on 'Latent TB'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328332\">",
"    <span class=\"h2\">",
"     Screening for STDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HIV-infected woman should be screened for evidence of sexually transmitted diseases, which can be associated with stillbirth, preterm delivery, and low birth weight. Screening for maternal syphilis infection is not only important in preventing congenital syphilis; one study demonstrated that maternal infection was associated with an increased risk of mother-to-child transmission (MTCT) of HIV as well [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8632752\">",
"    <span class=\"h2\">",
"     Toxoplasma serologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital toxoplasmosis is a concern among all pregnant women, but the seroprevalence varies based on geographic location. Toxoplasmosis titers are not routinely recommended for pregnant women in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/15\">",
"     15",
"    </a>",
"    ] because the prevalence is relatively low and the serology test must be performed in a reference laboratory. Thus, among HIV-negative women, evidence of acute infection is generally determined based on discovery of abnormal ultrasound findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/20\">",
"     20",
"    </a>",
"    ]. Congenital toxoplasmosis causes intracranial calcifications and neurologic disability in the neonate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in the setting of HIV infection, documentation of maternal T. gondii serologic status should be obtained during pregnancy. Women with evidence of potential primary toxoplasma infection during pregnancy or evidence of fetal infection should be referred to a Maternal Fetal Medicine specialist for evaluation.",
"    <strong>",
"    </strong>",
"    Therapeutic interventions are administered during pregnancy for affected fetuses. Pediatric care providers should be informed regarding any woman with a history of prior exposure based on serologic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8632759\">",
"    <span class=\"h2\">",
"     Cytomegalovirus serologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is the most common congenital infection, with a birth prevalence of 1 percent in the United States. It is the most common infectious cause of congenital hearing loss. While the majority of infected infants are asymptomatic, approximately 10 percent suffer major handicap or death and up to 25 percent develop sequelae later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unknown whether the fetuses of women with HIV infection are at higher risk for congenital infection. The majority of HIV-infected pregnant women (&gt;90 percent) have a history of CMV exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Thus, routine antibody screening for evidence of primary CMV infection in HIV-infected pregnant women is not indicated. Assessment of re-infection or reactivation of disease is the same as for nonpregnant HIV-infected adults.",
"   </p>",
"   <p>",
"    It is unknown whether therapy with hyperimmune globulin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    can prevent congenital infection and studies are ongoing. There is no fetal therapy currently recommended, therefore treatment should be considered only if it is necessary for active maternal CMV disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8632627\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain immunizations are generally recommended during pregnancy while others are specifically targeted for HIV-infected women.",
"   </p>",
"   <p>",
"    The only vaccines recommended for routine use during pregnancy are primary or booster doses of adult type tetanus and reduced diphtheria toxoids (Td or TdaP), and inactivated influenza vaccines (seasonal and H1N1) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/24\">",
"     24",
"    </a>",
"    ]. Immunizations during pregnancy are typically delayed until the second or third trimester, when possible, to minimize concerns about teratogenicity or miscarriage resulting from the vaccine or toxoid. However tetanus and influenza immunizations may be given during the first trimester because of special risks to the unimmunized pregnant woman, fetus, or newborn. As a general rule, live vaccines (eg, measles, mumps, rubella) are not used during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional routine immunizations that are administered to HIV-infected women include the following inactivated vaccines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumococcal vaccine",
"     </li>",
"     <li>",
"      Hepatitis A and B vaccines for those who have not been infected in the past",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunization of the HIV-infected patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22745505\">",
"    <span class=\"h1\">",
"     ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical intervention with antiretroviral (ARV) medications during pregnancy involves two separate but related goals: reduction of perinatal transmission and treatment of maternal HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/1\">",
"     1",
"    </a>",
"    ]. It is recommended that all pregnant HIV-infected women receive a combination ARV drug regimen, regardless of CD4 T lymphocyte count or plasma HIV RNA copy number, to prevent perinatal transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8632859\">",
"    <span class=\"h1\">",
"     CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis for the prevention of Pneumocystis pneumonia is recommended in pregnant women with a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    Because of theoretical concerns regarding possible teratogenicity associated with systemic drug exposures during the first trimester, aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    is preferred for prophylaxis in the first trimester because of its lack of systemic absorption. In the second and third trimester, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) as first line prophylaxis for pneumocystis;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    is an alternative agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One double-strength TMP-SMX tablet once daily is the preferred regimen. However, one single-strength tablet daily also is effective and might be better tolerated than one double-strength tablet daily. One double-strength tablet three times weekly also is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86989366\">",
"    <span class=\"h1\">",
"     PRENATAL FETAL MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86989378\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a first trimester ultrasound for gestational age determination, most experts recommend a detailed second trimester ultrasound evaluation of fetal anatomy in women who took a combination antiretroviral (ARV) regimen during the first trimester of pregnancy. While the available data suggest there is not an increase in overall birth defects with first trimester exposure to most ARV drugs, there are only limited data on newer ARV drugs in pregnancy and insufficient data to rule out birth defects that have a low prevalence in the general population (eg, neural tube defects with first trimester",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    exposure) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H7448918#H7448918\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Women with viral suppression on antiretroviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the possible association of low birth weight with ARV use, careful monitoring of fundal height to assess fetal growth is warranted; third trimester ultrasound is appropriate if there are concerns regarding fetal growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H3332952#H3332952\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Small for gestational age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86989398\">",
"    <span class=\"h2\">",
"     Invasive diagnostic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with viral suppression on a combination ARV regimen, amniocentesis does not appear to pose additional risk of transmission of HIV in utero, although data are limited. Patients should be on an effective ARV regimen with an undetectable plasma viral load before any invasive procedure. If amniocentesis or other invasive procedure is necessary and plasma viral load is not below detectable, consultation with an expert is recommended. HIV infection alone is not an indication for amniocentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link&amp;anchor=H1497450#H1497450\">",
"     \"Diagnostic amniocentesis\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence of the general safety of such procedures in the setting of viral suppression comes from several studies that cumulatively reported on 159 HIV-infected pregnant women who took a combination ARV regimen and underwent amniocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. None of them transmitted HIV to her child. This is in contrast to an apparent increased risk of transmission in older studies among women who were not receiving ARV drugs or were on non-suppressive ARV regimens and underwent amniocentesis. In the largest of these older studies, which analyzed data prospectively collected on a large cohort of pregnant HIV-infected women in France, there were non-significant trends towards increased transmission to the child after amniocentesis in women who had not taken ARV agents (3 of 12 [25 percent] versus 343 of 2113 [16 percent] without amniocentesis) and in those who took only a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV) or a dual nucleoside inhibitor regimen (3 of 49 [6.1 percent] versus 117 of 3556 [3.3 percent] without amniocentesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328285\">",
"    <span class=\"h1\">",
"     SUPPORT SERVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the individual&rsquo;s circumstances, provision of support services, mental health services and drug abuse treatment may be required. Such services are especially important in promoting adherence to daily medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86989334\">",
"    <span class=\"h1\">",
"     INTRAPARTUM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86989343\">",
"    <span class=\"h2\">",
"     Mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with plasma HIV RNA &lt;1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    on combination antiretroviral (ARV) regimens, the overall incidence of transmission of HIV is low regardless of the mode of delivery (cesarean section versus standard vaginal delivery) or duration of membrane rupture, and a further decrease in transmission risk with cesarean section in such women is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Thus, we do not typically schedule cesarean sections for these women, unless indicated for obstetric reasons.",
"   </p>",
"   <p>",
"    In contrast, in women whose viral load remains &gt;1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    prior to 38 weeks gestation (eg, women not taking ARV agents, women presenting late in pregnancy, or women not responding to their current ARV regimen), pre-labor cesarean section significantly decreases the risk of transmission to the child. This was illustrated by the findings of a meta-analysis of 15 prospective cohort studies performed prior to the widespread use of ARV agents during pregnancy, in which the incidence of HIV transmission to the infant with cesarean section was 8.4 percent (72 of 857 births) versus 16.7 percent (1280 of 7676 births) with vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/35\">",
"     35",
"    </a>",
"    ]. The reduction in risk was similar when adjusted for use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (versus nothing) and advanced HIV disease in the mother. A subsequent trial from the same time period that randomly assigned 436 HIV-infected women to cesarean or vaginal delivery produced similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, for these women, performing cesarean section at 38 weeks is recommended, before the likelihood of labor onset and rupture of membranes.",
"   </p>",
"   <p>",
"    For women who present in labor or with ruptured membranes prior to scheduled cesarean section, management must be individualized, and take into account the duration of the rupture of",
"    <span class=\"nowrap\">",
"     membranes/labor,",
"    </span>",
"    current ARV regimen and HIV RNA level.",
"   </p>",
"   <p>",
"    Prior to the widespread use of combination ARV during pregnancy, duration of membrane rupture was associated with risk of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/37\">",
"     37",
"    </a>",
"    ]. However, in a more recent prospective study of deliveries between 1996 and 2008, there were no cases of HIV transmission among 493 pregnant HIV-infected women on combination ARV regimens with HIV RNA &lt;1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    near delivery, 144 of whom had rupture of membranes more than four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/34\">",
"     34",
"    </a>",
"    ]. Among the 146 women on combination ARV regimens who had HIV RNA &gt;1000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (55 of whom had cesarean while the others had vaginal delivery), perinatal transmission was 3.8 percent if duration of membrane rupture was less than four hours compared with 4.9 percent if four or more hours, and this difference was not statistically significant. Only viral load above 10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was an independent risk factor for perinatal transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22163882\">",
"    <span class=\"h2\">",
"     Preterm premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;When membrane rupture occurs before 37 weeks gestation, decisions about timing of delivery should be based on best obstetrical practices, taking into account risks of prematurity for the infant.&nbsp;The presence of HIV infection of the mother should not change management. Administration of antenatal corticosteroids to accelerate fetal lung maturity should be given if appropriate, as no data exist to suggest that these recommendations need be altered for HIV-infected women.&nbsp;When the decision is made to deliver, route of delivery should be according to obstetrical indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86989351\">",
"    <span class=\"h2\">",
"     Intrapartum antiretrovirals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should continue taking combination ARV as much as possible during labor and delivery or scheduled cesarean section. Additional administration of intrapartum intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV) depends on the maternal HIV viral load near the time of delivery. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H8630301#H8630301\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Intrapartum antiretrovirals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H336639879\">",
"    <span class=\"h2\">",
"     Other intrapartum interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetric management should minimize the duration of fetal exposure to maternal fluids and blood, and avoidance of invasive fetal monitoring is recommended. The possible risks of interventions during management of labor should be weighed against the obstetrical indications and benefits. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22745577\">",
"    <span class=\"h1\">",
"     INFANT PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis is administered to the infant after birth to decrease the risk of HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/1\">",
"     1",
"    </a>",
"    ]. It protects the infant from virus that might have obtained access to the fetal circulation during labor or through exposure to virus during passage through the birth canal. The details of infant antiretroviral prophylaxis regimens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H8627914#H8627914\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Infant prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328432\">",
"    <span class=\"h1\">",
"     COUNSELING REGARDING BREASTFEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to delivery, the HIV-infected woman should be counseled that breastfeeding is not recommended by the United States Public Health Service, due to concerns regarding risk of mother-to-child transmission (MTCT) of HIV. These recommendations also apply to the woman who is taking combination antiretroviral (ARV) drug regimens, since trials in resource-limited settings demonstrate that ARV medications significantly decrease, but do not eliminate, the risk of HIV perinatal transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with maternal plasma, drug levels in breast milk vary widely between drugs. Administration of some medications may lead to drug concentrations as much as three times above maternal plasma (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ), whereas others may lead to drug levels significantly less than those in maternal plasma (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/4/15433/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The toxicity of chronic ARV exposure of the infant via breast milk is unknown. Observational studies and clinical trials in developing countries suggest that while use of combination ARV drug regimens may lower the risk of breast milk transmission, it does not eliminate it. Therefore, given the availability, affordability, and safety of replacement feeding in the United States, HIV-infected women should not breastfeed.",
"   </p>",
"   <p>",
"    In contrast, avoidance of breastfeeding in infants born to HIV-infected mothers in resource-limited settings is associated with increased infant morbidity and mortality. The prevention of HIV perinatal infection in breastfeeding women in resource-limited settings is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448564\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comprehensive medical care of HIV-infected pregnant women is associated with favorable maternal health outcomes and low rates of perinatal HIV transmission. (See",
"      <a class=\"local\" href=\"#H10063254\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough history and physical examination should be performed in the HIV-infected pregnant woman to see if there are health concerns in the mother, which may also affect the well-being of the fetus. (See",
"      <a class=\"local\" href=\"#H7447182\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal care providers should address potentially modifiable behaviors, which have been associated with an increased risk of HIV perinatal transmission, such as cigarette smoking, illicit drug use (eg, cocaine, heroin), and unprotected intercourse with multiple partners. (See",
"      <a class=\"local\" href=\"#H10063269\">",
"       'General counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accurate determination of fetal gestational age is particularly important among pregnant women with HIV infection, since scheduled cesarean delivery at 38 weeks gestation may be necessary to decrease the risk of perinatal HIV transmission if maternal viral load is &gt;1000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      near term. (See",
"      <a class=\"local\" href=\"#H10063283\">",
"       'Determination of gestational age'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H86989343\">",
"       'Mode of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant HIV-infected women should be screened for both hepatitis B and hepatitis C virus infections since coinfection is common in HIV-infected patients due to shared routes of transmission (eg, injection drug use). (See",
"      <a class=\"local\" href=\"#H8632998\">",
"       'Testing for viral hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccines recommended for routine use during pregnancy include primary or booster doses of adult type tetanus and reduced diphtheria toxoids (Td or TdaP), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      . Pneumococcal vaccine and hepatitis A and hepatitis B vaccines are also indicated in HIV-infected women. (See",
"      <a class=\"local\" href=\"#H8632627\">",
"       'Immunizations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H13#H13\">",
"       \"Immunizations during pregnancy\", section on 'Immunization issues during pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy itself is associated with a decline in absolute CD4 count number, which may be related to increased plasma blood volume; however, there is usually no effect on the CD4 percentage. Therefore, some clinicians prefer to monitor the CD4 percentage during pregnancy, although treatment recommendations remain predicated upon absolute CD4 counts. (See",
"      <a class=\"local\" href=\"#H10063319\">",
"       'Interpretation of CD4+ T cell counts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma HIV RNA is monitored frequently during pregnancy to confirm attainment and maintenance of viral suppression. Close monitoring is desired to confirm the effectiveness of the patient&rsquo;s antiretroviral drug regimen since higher levels of HIV RNA are associated with increased risk of perinatal transmission of HIV infection. (See",
"      <a class=\"local\" href=\"#H10063326\">",
"       'Viral load measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to delivery, the HIV-infected woman should be counseled that breastfeeding is not recommended by the United States Public Health Service, due to concerns regarding risk of mother-to-child transmission of HIV. (See",
"      <a class=\"local\" href=\"#H328432\">",
"       'Counseling regarding breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrapartum management, including the mode of delivery and the need for intrapartum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      , depends on the plasma viral load level of the mother. (See",
"      <a class=\"local\" href=\"#H86989334\">",
"       'Intrapartum management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H8630301#H8630301\">",
"       \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Intrapartum antiretrovirals'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All infants born to HIV-infected mothers should receive antiretroviral prophylaxis. (See",
"      <a class=\"local\" href=\"#H22745577\">",
"       'Infant prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H8627914#H8627914\">",
"       \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Infant prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, July 31, 2012. file://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (Accessed on August 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/2\">",
"      Burns DN, Landesman S, Muenz LR, et al. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr 1994; 7:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/3\">",
"      Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavior during pregnancy and perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 1996; 10:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/4\">",
"      Rodriguez EM, Mofenson LM, Chang BH, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996; 10:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/5\">",
"      Bulterys M, Landesman S, Burns DN, et al. Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/6\">",
"      Turner BJ, Hauck WW, Fanning TR, Markson LE. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/7\">",
"      Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med 1996; 334:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/8\">",
"      Mongelli M, Wilcox M, Gardosi J. Estimating the date of confinement: ultrasonographic biometry versus certain menstrual dates. Am J Obstet Gynecol 1996; 174:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/9\">",
"      Neilson JP. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev 2000; :CD000182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/10\">",
"      Yang H, Kramer MS, Platt RW, et al. How does early ultrasound scan estimation of gestational age lead to higher rates of preterm birth? Am J Obstet Gynecol 2002; 186:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/11\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 101: Ultrasonography in pregnancy. Obstet Gynecol 2009; 113:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/12\">",
"      Mehta S, Manji KP, Young AM, et al. Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women. Am J Clin Nutr 2008; 87:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/13\">",
"      Tuomala RE, Kalish LA, Zorilla C, et al. Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study. Obstet Gynecol 1997; 89:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/14\">",
"      Miotti PG, Liomba G, Dallabetta GA, et al. T lymphocyte subsets during and after pregnancy: analysis in human immunodeficiency virus type 1-infected and -uninfected Malawian mothers. J Infect Dis 1992; 165:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/15\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/16\">",
"      Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis 2007; 44:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/17\">",
"      Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/18\">",
"      Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/19\">",
"      Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS 2006; 20:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/20\">",
"      ACOG practice bulletin. Perinatal viral and parasitic infections. Number 20, September 2000. (Replaces educational bulletin number 177, February 1993). American College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 2002; 76:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/21\">",
"      Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/22\">",
"      Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999; 341:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/23\">",
"      Quinn TC, Piot P, McCormick JB, et al. Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA 1987; 257:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/24\">",
"      Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:817.",
"     </a>",
"    </li>",
"    <li>",
"     Antiretroviral Pregnancy Registry Steering Committee (2012). Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989 - 31 January 2012. Wilmington, NC: Registry Coordinating Center; 2010. file://www.APRegistry.com (Accessed on July 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/26\">",
"      Ekoukou D, Khuong-Josses MA, Ghibaudo N, et al. Amniocentesis in pregnant HIV-infected patients. Absence of mother-to-child viral transmission in a series of selected patients. Eur J Obstet Gynecol Reprod Biol 2008; 140:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/27\">",
"      Mandelbrot L, Jasseron C, Ekoukou D, et al. Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les H&eacute;patites Virales French Perinatal Cohort. Am J Obstet Gynecol 2009; 200:160.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/28\">",
"      Coll O, Suy A, Hernandez S, et al. Prenatal diagnosis in human immunodeficiency virus-infected women: a new screening program for chromosomal anomalies. Am J Obstet Gynecol 2006; 194:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/29\">",
"      Somigliana E, Bucceri AM, Tibaldi C, et al. Early invasive diagnostic techniques in pregnant women who are infected with the HIV: a multicenter case series. Am J Obstet Gynecol 2005; 193:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/30\">",
"      Maiques V, Garc&iacute;a-Tejedor A, Perales A, et al. HIV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol 2003; 108:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/31\">",
"      European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/32\">",
"      Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/33\">",
"      Forbes JC, Alimenti AM, Singer J, et al. A national review of vertical HIV transmission. AIDS 2012; 26:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/34\">",
"      Cotter AM, Brookfield KF, Duthely LM, et al. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol 2012; 207:482.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/35\">",
"      The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med 1999; 340:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/36\">",
"      European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/37\">",
"      Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995; 173:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/38\">",
"      Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/39\">",
"      Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/40\">",
"      Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/4/15433/abstract/41\">",
"      Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit 2008; 30:611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13972 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15433=[""].join("\n");
var outline_f15_4_15433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7448564\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10063254\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7447182\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10063269\">",
"      GENERAL COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10063283\">",
"      DETERMINATION OF GESTATIONAL AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10063311\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7447723\">",
"      Hematocrit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10063319\">",
"      Interpretation of CD4+ T cell counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10063326\">",
"      Viral load measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10063333\">",
"      Drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8632998\">",
"      Testing for viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7448597\">",
"      Testing for tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H328332\">",
"      Screening for STDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8632752\">",
"      Toxoplasma serologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8632759\">",
"      Cytomegalovirus serologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8632627\">",
"      IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22745505\">",
"      ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8632859\">",
"      CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86989366\">",
"      PRENATAL FETAL MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86989378\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86989398\">",
"      Invasive diagnostic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328285\">",
"      SUPPORT SERVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86989334\">",
"      INTRAPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86989343\">",
"      Mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22163882\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86989351\">",
"      Intrapartum antiretrovirals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H336639879\">",
"      Other intrapartum interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22745577\">",
"      INFANT PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328432\">",
"      COUNSELING REGARDING BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448564\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_4_15434="Hepatic NRH light low";
var content_f15_4_15434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54880%7EGAST%2F76034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54880%7EGAST%2F76034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular regenerative hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This low power (4x) view of a liver biopsy with a reticulin stain shows a vague nodular pattern. The aggregation of hepatocytes with abundant cytoplasm surrounded by narrow sheaths of compressed cells gives the liver a nodular appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Matthew Turner, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular regenerative hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power (40x) view of the reticulin stain showing hepatic cords that are compressed (left), expanded (right), have a high nucleus to cytoplasm ratio, and abundant cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Matthew Turner, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15434=[""].join("\n");
var outline_f15_4_15434=null;
var title_f15_4_15435="Cytotoxic T cell targets";
var content_f15_4_15435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of tumor-specific and lineage-specific targets for cytotoxic T cells",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumor-specific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiotype - B cell malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T cell receptor - T cell malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBV epitopes - EBV-associated lymphomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oncogene products - (eg, bcr/abl in CML, Wilms tumor 1 in acute myeloid leukemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lineage-specific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MAGE proteins - melanomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinase III - acute myeloid leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Her 2 neu - breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoembryonic antigen - solid tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minor histocompatibility antigens - hematopoietic malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD19 - CD19 positive hematopoietic malignancies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15435=[""].join("\n");
var outline_f15_4_15435=null;
var title_f15_4_15436="Paget disease breast surgery";
var content_f15_4_15436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of Paget disease of the breast with surgery alone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Local Recurrence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median F/U (mos)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Polgar C; 2002",
"       </td>",
"       <td rowspan=\"2\">",
"        33",
"       </td>",
"       <td>",
"        No mass (30)",
"       </td>",
"       <td rowspan=\"2\">",
"        Cone excision only",
"       </td>",
"       <td rowspan=\"2\">",
"        11 (33 percent)",
"       </td>",
"       <td rowspan=\"2\">",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mass (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Dixon AR; 1991",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        No mass",
"       </td>",
"       <td>",
"        Simple mastectomy",
"       </td>",
"       <td>",
"        2 (5 percent)",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        10",
"       </td>",
"       <td>",
"        No mass",
"       </td>",
"       <td rowspan=\"2\">",
"        Nipple-areolar resection + resection underlying breast tissue/calcifications",
"       </td>",
"       <td rowspan=\"2\">",
"        4 (40 percent)",
"       </td>",
"       <td rowspan=\"2\">",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcifications adjacent to nipple on mammogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Lagios MD; 1984",
"       </td>",
"       <td rowspan=\"2\">",
"        5",
"       </td>",
"       <td>",
"        No mass",
"       </td>",
"       <td>",
"        Nipple-areolar resection (n = 4)",
"       </td>",
"       <td>",
"        0 (0 percent)",
"       </td>",
"       <td rowspan=\"2\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal mammogram",
"       </td>",
"       <td>",
"        Partial nipple-areolar resection, (n = 1)",
"       </td>",
"       <td>",
"        1 (100 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paone JF; 1981",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        No mass",
"       </td>",
"       <td>",
"        Nipple-areolar resection",
"       </td>",
"       <td>",
"        0 (0 percent)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Dixon AR, et al. Br J Surg 1991; 78:722. Lagios MD, et al. Cancer 1984; 54:545. Paone JF, et al. Cancer 1981; 48:825. Polgar C, et al. Cancer 2002; 94:1904.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15436=[""].join("\n");
var outline_f15_4_15436=null;
var title_f15_4_15437="Minor RBC antibodies pregnancy1";
var content_f15_4_15437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minor red blood cell antibodies associated with hemolytic disease of the newborn",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Blood system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific antigens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severity of hemolytic disease of the newborn (HDN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Kell",
"       </td>",
"       <td>",
"        K",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        k",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ko",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kp(a)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kp(b)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Js(a)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Js(b)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Duffy",
"       </td>",
"       <td>",
"        Fy(a)",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fy(b)",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fy(3)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Kidd",
"       </td>",
"       <td>",
"        Jk(a)",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jk(b)",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jk(3)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Lewis",
"       </td>",
"       <td>",
"        Le(a)",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Le(b)",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        I",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        i",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"11\">",
"        MNSs&nbsp;",
"       </td>",
"       <td>",
"        M",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        s",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        U",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mi(a)",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mt(a)",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vw",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mur",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hil",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hut",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Lutheran",
"       </td>",
"       <td>",
"        Lu(a)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lu(b)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Diego",
"       </td>",
"       <td>",
"        Di(a)",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Di(b)",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xg",
"       </td>",
"       <td>",
"        Xg(a)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        P",
"       </td>",
"       <td>",
"        PP1P(k)",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P1",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Weinstein L. Clin Obstet Gynecol 1982; 25:327 and Reid ME, Toy PTCY. In: Hematology of Infancy and Childhood, 5th ed, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia, 1998, p. 1768.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15437=[""].join("\n");
var outline_f15_4_15437=null;
var title_f15_4_15438="Supplementation after RYGB";
var content_f15_4_15438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Supplementation after Roux-en-Y gastric bypass and gastric sleeve procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Supplement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Representative preparations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Multivitamin with minerals and iron, one or two per day, each chewable tablet (or liquid equivalent) minimally containing",
"        <sup>",
"         &Delta;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin A",
"       </td>",
"       <td>",
"        500 mcg (1600 units)",
"       </td>",
"       <td rowspan=\"10\">",
"        <p>",
"         Multivitamins with minerals (including iron):",
"        </p>",
"        <p>",
"         Representative trade names (US) include: Centrum&reg; (NOT Centrum Silver&reg; as mineral content is too low), Centrum Performance&reg;, One-A-Day Maximum&reg;, Equate Complete Multivitamin for Adults",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B1 (thiamine)",
"       </td>",
"       <td>",
"        1.2 mg",
"       </td>",
"       <td>",
"        <p>",
"         Thiamine (optional)",
"        </p>",
"        <p>",
"         Erythrocyte transketolase activity (optional)",
"        </p>",
"       </td>",
"       <td>",
"        Thiamine deficiency has been associated with intractable vomiting following bariatric surgery and Wernicke encephalopathy has been reported. See text.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin E",
"       </td>",
"       <td>",
"        10 mg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin K",
"       </td>",
"       <td>",
"        Male: 120 mcg; Female 90 mcg",
"       </td>",
"       <td>",
"        &nbsp;Prothrombin Time/INR (optional as a measure of vitamin K status)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron",
"       </td>",
"       <td>",
"        10 mg elemental",
"       </td>",
"       <td>",
"        TIBC, ferritin, transferrin, CBC",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folic acid",
"       </td>",
"       <td>",
"        400 mcg",
"       </td>",
"       <td>",
"        RBC folate (optional)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biotin",
"       </td>",
"       <td>",
"        30 mcg",
"       </td>",
"       <td>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selenium",
"       </td>",
"       <td>",
"        55 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zinc",
"       </td>",
"       <td>",
"        Male: 11 mg; Female: 8 mg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Zinc deficiency may be associated with chronic diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper",
"       </td>",
"       <td>",
"        2 mg",
"       </td>",
"       <td>",
"        Serum copper",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Calcium and vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Calcium citrate",
"        </p>",
"        <p>",
"         Calcium carbonate (see comment)",
"        </p>",
"       </td>",
"       <td>",
"        1200 to 1500 mg (elemental calcium) per day preferably in&nbsp;two equally divided doses",
"       </td>",
"       <td>",
"        <p>",
"         Elemental calcium content:",
"        </p>",
"        <p>",
"         Tablets, capsules: 180, 200, 250 mg",
"        </p>",
"        <p>",
"         Effervescent tablet: 500 mg",
"        </p>",
"        <p>",
"         Oral suspension: 760 mg per 5 mL",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         25-Hydroxyvitamin D",
"        </p>",
"        <p>",
"         Intact PTH (optional)",
"        </p>",
"       </td>",
"       <td>",
"        Calcium citrate preparations may be better absorbed than calcium carbonate under conditions of reduced gastric acidity but require consumption of more tablets. Do not take within two hours of iron supplement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D3 (cholecalciferol)",
"       </td>",
"       <td>",
"        800 units per day",
"       </td>",
"       <td>",
"        <p>",
"         Tablets, capsules: 400, 1000, 2000 units",
"        </p>",
"        <p>",
"         Chewable tablet: 400 units",
"        </p>",
"        <p>",
"         Oral drops: 400 units per drop",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Iron and ascorbic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Ferrous fumarate",
"        </p>",
"        <p>",
"         Ferrous gluconate",
"        </p>",
"        <p>",
"         Ferrous sulfate",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         40 to 65 mg (elemental iron) per day for premenopausal women",
"        </p>",
"        <p>",
"         18 to 27 mg (elemental iron) per day for others",
"        </p>",
"        <p>",
"         May be included in multivitamin",
"        </p>",
"       </td>",
"       <td>",
"        Combination (eg, Vitron-C&reg;) ferrous fumarate (65 mg elemental) with ascorbic acid (125 mg); ferrous sulfate oral liquid: 44 or 60 mg elemental per 5 mL; ascorbic acid liquid: 100 mg/mL",
"       </td>",
"       <td>",
"        Iron studies, ferritin, CBC",
"       </td>",
"       <td>",
"        Iron supplementation is based on monitoring. Iron is contained in the multivitamin-mineral tablet and additional supplementation is not recommended unless the patient has documented iron deficiency. If additional supplementation indicated, 100 to 150 mg ascorbic acid enhances iron absorption under conditions of reduced gastric acidity. Do not take within two hours of calcium supplement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vitamin B12 (cyanocobalamin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oral tablet",
"       </td>",
"       <td>",
"        500 to 1000 mcg per day",
"       </td>",
"       <td>",
"        Tablet: 250, 500, 1000 mcg",
"       </td>",
"       <td rowspan=\"5\">",
"        CBC, Vitamin B12 (methylmalonic acid, homocysteine optional)",
"       </td>",
"       <td rowspan=\"5\">",
"        B12 deficiency is a frequent complication within one year of RYGB surgery in absence of adequate supplementation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sublingual or buccal tablet",
"       </td>",
"       <td>",
"        500 to 1000 mcg per day",
"       </td>",
"       <td>",
"        Sublingual tablet or lozenge 500 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sublingual spray",
"       </td>",
"       <td>",
"        400 mcg per day",
"       </td>",
"       <td>",
"        200 mcg per spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intranasal spray",
"       </td>",
"       <td>",
"        500 mcg once per week",
"       </td>",
"       <td>",
"        500 mcg per 0.1 mL intranasal spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intramuscular injection",
"       </td>",
"       <td>",
"        1000 mcg IM once per month or 3000 mcg IM once every&nbsp;six months",
"       </td>",
"       <td>",
"        1000 mcg per mL injection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with deficiency states will need treatment beyond these recommendations.",
"    <div class=\"footnotes\">",
"     IM: intramuscularly; TIBC: total iron binding capacity; RYGB: Roux-en-Y gastric bypass; PTH: parathyroid hormone; CBC: complete blood count; RBC: red blood cell.",
"     <br>",
"      * Maintenance dosage for adult, oral administration, unless specified otherwise.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Routine lab monitoring at baseline and every&nbsp;three to&nbsp;six months during first year, then annually thereafter. See text for additional information.",
"       <br>",
"        &Delta; Multivitamin should provide US Food and Drug Administration daily recommended intake for other vitamins and minerals. Iron containing multivitamin preparations that do not contain calcium may be preferred. Calcium should be administered as a separate preparation at least two hours before or after multivitamin with iron supplements to increase absorption.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <ol>",
"      <li>",
"       Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic &amp; Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008; 14 Suppl 1:1.",
"      </li>",
"      <li>",
"       Snyder-Marlow G, et al. Nutrition Care for patients undergoing laparoscopic sleeve gastrectomy for weight loss. J Am Diet Assoc 2010; 110:600.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15438=[""].join("\n");
var outline_f15_4_15438=null;
var title_f15_4_15439="Prostatic adenocCA core biopsy";
var content_f15_4_15439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prostate adenocarcinoma in a core needle biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 278px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEWAXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDYa2WOLaiP9qBLtLuyoGegA7VsWlkRp8V1OJMgFoXQ8oB3x75rLjZmSXe2UcbQQuMg4/lV7T7m4tbdrMMQyjbHIFyVzivZndqy3PSlCbhoFreJqFuj3DTiPaQZI2A5AyDj36U6GGO3cTM4UnDF2PBOOPxrQtLG1jzI0wPO8jdt5x1x35rPaI3juiMV8vEi7sFGAPI+vSpTTbUdEVGyTL8N7ODHIDLG+CQxb7w6jHpW3oviQW0Tm9llnhIDByAWVj1X6Cuds/szTxQMxEwmwUJIUp6D9MYq9dKro8QTCplvL/8Ar1E6cXo0QqXtNJHa6drMOoak9paxM6xoHeXgAAjjH5GtpQOBivL/AAhqkOlNqF4ySz3MygGFRyMZwPYf411/h7xQNTP+k2n2FcdZJVJJ7YHeuWtQcH7q0RxVKTTfLsjpRjOMGnjHvTIZo5RlGGM8e9TgcVzGIgwacBS4pwWkMQD3p4FLj2pwHtQAgFOApQKXFACAUuKWigBMUuKKKBhiiiigAooooAKKKKACiiigAooooAKaRTqKAGEUmKkxSGgRGRTSKkIpG4oGQkVmatfSWd5pEMaqy3t2bdy3VV8qR8j3ygrXNc94oYJqfhlnIVRqJJJOAB9mmqZbAbqLnrTii+lRRXls0butxCUQZdg4wo9z2pDfWhtDdC6gNsBnzvMGzHT73SqEP2DPSkZB6UsMiTxrJC6yRsMqynII9jT2HrQBSmHlo59AT+lZ2gXj6loOnX0yoklzbRzMq9AWUEgfnWndYMUnH8J/lWJ4LA/4Q3Qf+vGD/wBAFK/vDNVl60wrzUxFMKiqAi2fSipNv0ooA8S2tKu0EbMlsDtjjn0pycRhtuDtJXB4B96uwFIuHUK8meFIPPoKgMU4mUyLGFJwVWTJX6+9ete+h7Skr2uSWsaO6SwyrOFXdl4ypXjlfT15qvbndLci0keSCY4wedp9Py4p9za3sun3lpYEzTvHuAGFKD+I+9Os5LMOZIJCyzBII0xh8Dgs3uetWtbsxbjGyevc3LhY723Z7DZvcKznHKqMcAdj0qo98hmeFY2DyMsauPlBPp9e9NtPLdroKrp5RbKF/wAOo7d/TmtGOyTVoN9iBDImHZfRux/OstI77EKSpqyYlxp76dceVK3mNImQygKM5OQf0q9or29rfCG7t4XEuUM7feUdQDnjFYdxO9vdtHq7NPI42ERsOG9M9sZrZ0y0eeM/ZokW3+7umYszep9/pxRNe77zIb5o2m/mdnaLFJJEsLR4Vt6hfQden1rTYuNuxQ3ODk4wK4nR7q60jUmilhzaOxCsqfM+OprpND1WTUJJ1kh8sIeDjH4c9fr05rhqU2tehy1KTjqtUbAFOFIKcvNYGIuKcKQU6gYUooFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBDSEDvTqQ0CGHrXC/Fy2W80O0tHS5dbiS4hK2sfmSkNZ3C/IuRubngZ5ruzXLeNrG11G68NWt/AlxbvqWWjkGQcW8xH61M/hY0eH2nhbWV8EeI7DS9AuzpSXFiUMumizvL+KNsyK0Y5fHUEjJyetXZfDupvaz3sWg36+Gj4rivzpf2Rg7WwXDP9nxkruwdmMnHSvaj4N8Nf9APT/wDvyKafBvhv/oB6f/35FHvBc5X4WaZq2m/D7VIvss9jJPdXk2n20q+W8ETkmNdp+5zk4PTNcemu+OLzSYkisfEkF1b+HbhZ2ms3XzL5Su0rx8zdcevavWD4O8N/9APT/wDvyKb/AMIf4b/6Aen/APfkUe8Gh5LeWvja0bVJItR8TzraSabPAkke5ZjKP9JBwnzKuOVGAuTkV6z4K/5EzQf+vCD/ANFio7jwd4bMEoOhafgow/1I9Kl8FLjwZoAHAFhAB/37FCvfUDWNMankYNNINUIbRTsH/JooGeUjS76GeWCaMysw4ZUDADtziqUc4ilMyJwCc4XivRL6F/IuHB3rs/1bcAY68jnkVwhgARpoCzWocD94oHYEA456HvXoUqnPud+Frc11bUyZ2k1GxumKtbiRTEMHg57ita8SGXS1vYYTG9syxSBAMFgAN1MnjSQyRRxhUOBvB/z600RzW9k9msbmyRtzvjkZx19RxXRp0NJ30bexZ0cg39wyIjsLcEx4Clh7D2x2q9HHdac0ctrOjJcxKCwH3SOcZ9Dn9K42/sobvWY5LUOI0IIk5XYQcgZ9c5NdJY6h5mlmwSSIPaf607+i/wAOQeRjPX2oqQ0T7kqk3r0L9vcM+obZYo1R8K6P/EeQSD2boffmt3w/OItJugE826tXYmLOCe4x7Hsa4q/v/sttHdXFrFcbJld2D7mEfTcBnBPvXXXWo2jpctZO2+ONjGzoVDAdVORyKyqxdrWMakb7FC4vPOtjdRXEhaUFyxJPlAkfKB7f0qSOSe2Y3WlpNJGHAWZ0yTkc5xzisO1uo0jtjvaKYZDyjJGD7d66bT9Sgs2SCy/0mB03ZYkfvc/QcYxVSjyqyRpPmaUUjpdB1g6hKLVprdbuFA88HJkUHOPauhArzi11GfTVWO2aNW87MmEDEA8vyfrXWaN4gt71Y0l/d3BbYVAyM/WuKrRa1S0OatQcGbgpQBRS1zGAUUUUxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSGlooAbiuf8T/8hXwx/wBhI/8ApNNXQ1h+IreafUvDzwxM6QX5klI/gXyJVyfbLAfjUz+FiRsGmkU880hqgImFNNSH6Uw59qAIp/8AUSf7p/lWN4K/5EzQf+vCD/0WK2pQTFIBySpAH4Vl+Fbea08LaNbXCGKeGzhjkRuqsEAINT9oZon6U1qec+opjAkdeaoQ3FFLg0UDM1RXF+LFltr648kGS3aLzXiB2ENyAVIHPToa7VSM9DWT4j037XELiGRo7lBtVwM4GeuPbmtaUuWWoU5csrs4y3j8mIbmLOAGLf3jiktpp5I54BG0glIGQOfTH0FUhf37XDLdsjTLJt82NSoZRgD8elW4iJpGf7QIDGu+MKOWbPY+g6mvT5erPTnNSj/W5f1JrjTLVLLyYY7fG5iuWDNg8ZPfvXOWtzZ2utsZI1uAoHnLG3ykHuc479QeOK6G3smvLyW4uNjHcu5kJJ/HNMTw5BPrUitOtv5CA70ALODk857DP604TjG/M/UmyhG0mNSO1tLi5azC+TNF+7KDGzPYg9eM9OtV11G4nuI2gtvtZt1AjiQ7Rt7716gEZ56dKlJmt5IbdLV2ntS6ybFypUtndjPGQT+dS2FytoAq3EgtJEwbd41bGOpDA5PuPam9rvUa1Vkrst3MEclhaLdQqkrnzCpO4p1IGTjPHenNaxQX4ttSEssaxcRxfOd5wQe1QWiLfxK/kTyTKxwyygIB6qPoM496sQrcWkiTeW0D+UVdhg71yTnPYngVO2lyNUuUiSAzjam4MGACjHz5Hv2x/KtBpLu2liTy/JlSMRq0bZ+XJ+nNQxFFYly9uRH5iOBy3pg9KWC6ae0e3jVTI7bjIR8xPcfSk7v0NZXbutTsdH1W4VYIb5kZwMSPnBHpmujzxmvL9Pjit7p5eqzfK+4noBjGPr/M12+gXjTxC3nHzogIJ7j0+orhr0lHVHLXoOCubNFFFcxyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhopKQhDTfxpxxTTimAzOTTT0p5phpANNIaU00imMaaY3HrTzUZoAM+xopKKAM9KnVajQAVMtMgzb/AESC+guYnJxMDgED5G9RXnc6PaeY24OISVbjOG6ZxjmvW1+tcn4l0W4W6lv7Vx9nK5lTGWHqQO4rqw9Wz5Wzqw1RaxkctowLSvBNd+ShTcCiFnI/+tn8q0p7aSWwa8Z9zxr5ZO3A2jjLe+Mf1pbawvplxaoktsziTcxCkEf3T7jtVy5kFl/aNjGDJHLjbn+Ansc+1dUpXlpudDqNS01ZV0yHyUVo2NvO7nypSONhXGG/EcGqjpPpV0Y7hDMhJY/THPTnJ9R1rTtoF1W5jsrSdI5IzvBYElgOucdugrtp9MiuIfLljib5QMlQcEd+lZyrKD16kTqqnLU8zN8vnRXNsIUUDy3bzCN/px/exUzCMTjzYmjkZCMuCDkn0x071rv4cOka2l69rPewpKXtxG+SvHCsD6HJz/8AqrqLbTFu3Goa5bwNOgIjjPzLEnv2Lepqp14Rs1sX9YUVpscbb6Zc3Fu8kcKGz3f68TZCAei+vGPzqw0EdpbCUyl0kbYYwm1s4z681vajbCzX/R5tmnXJ/wBUEyI3HPygcgHnPvVHUI7WKKwuIlMmJWidmU7lJAOQPwNSqjkKE3ujHnmDyLFGXEKDdjGeMjk+nWtC3u2gkEsMjDAAQtgsPX2rNjee5e6awjG3zcN8w3Nk/d56/hSX88ltHK10Y0kUZ3qyuuB1OR3rVxvobuSlo3Y9H0zUI75XCkb48B8e4zxV6vLtPlT7bDqWmanPJb3EAKRuNmzgH8fxrutI1ZZ08q7ZUuFHJ6BveuGtQcNUcdShZc0NUa9FUdO1Wy1Jpls5xI0LbJBgjafxq9WDTTsznaa0YUUUUhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJS0YpAMam1JimkUARt0ppxUmKQigREaQ09hTDTGMNMIqXBNIykdaAIse1FPxRQBnLUqjI6VGhqZD7UyB6+4p5UOjKRwRg5Gaap5xUin160gORIk0O7NrJcRi1f5oXMeQG6lSAcj2osbZ9Uia8NwVmZmUhQCq44HB56e/eulu9Os7tneWCPznQx+bsG8L6ZrAbSrmxFyLRzZ24UMTner9ic9VOMZ7V1QqKS8zojO/WzKFprtro92kdzERLbwNDiJd3nMXGMEDgcZyfWr58aujFn0qYRBgpO7DDjPQgc4BrP0aSztLlxMybFj+XJyDznPuaranqFvqephdsoMWPLiCHc59TjoK39lCUtVc2dJczTXzO9a4KTK1sPM80LI+49E9hWWJpJ59xlcF8h1wcBe/0xXO6T4hWZmhlhFz9nHlN8zI0ZHv3FdO2uWzyxrDO4jcBAMDC47njPJ+WsHSlTewnRlDRK5gXGuLdXSpEm6ONnEeARkZ68jio4LmS7lkklxHEv7vYTwR13fXtVgvH5D2409IrlflkfZnBzwS3YYqklqtyrRowSFI187ysgMxHHsO/T0rpjypWtY1g0tGjLaVbfUWZQjMr7AWxg56fh061oQ3Npb25i8lJL9icsyDZktg4HeodRt1JjiiV4hGMNKQCCvYZPfgGmm2e1UuwzNLmRSxBZuPvYHSt3yySNfZ8zu9LlzT7Ce+u4VjjCWsTgTADar/7I9h7elW4oo7O6vLVpnMcTmNJM7sZH8X04rQj1Wwt7TZbzxCNQMYOTz04HPemW8qXUk8xgMcVw5JBOCTgDJ+uKwcpO91oKMpc13scyJJbG6jS4vW3W+WQQrsw2OST3Pr1613HhbXIb4G2a5jeZRlFMgZyvqfX/AOvWBq9hZyK0t2ojiUbw6Hkcccd+Mio9NgMVnF9nLwwspzIqJEzc9+d3/wBanVjGrC73M6sFJWseigg5wQe1LXB2s93ZRtHYXLjMnmfvMOCe+cjJBOM4Oa6vRtSF/Cd20TL94L0/CuGpRcNehyzpSjqaNFFFYmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTTTsUhFIBhpDTiKbigBhpvXinlRSDANACgACmydKcWqNjmgBlFJtFFAGclTKMVAnWp15qiGSKOakA6U1aetIBwFOAyMEZHekFPU8UDOe1rTC99a/ZLFCm198gAAXjjjrnOMfjWZpAsLUXS3wEVy0haQS9SD0+oruBWXqmhWeoxqkkaIRxuVAWHpjPTmt4VtOWRtCppyyOF1F0luPPtrbZajCFYvlZuTwT70g0x7fTxdM6xDOVQZITJ+7156n8at67p19Z3FygtWOnxoNsoC7SOn5jvSHT7ufc0ZnuLEoGLvtAz7EHBH9a7YyXKrM66bUuVJ6E0FzdBJ4YYd654kzkHI9D1pYZ7a20JVhhmnuz8xREw2c4Gc/iKqBxbMotmkyq5wjH5eccnoPxqzD5MmkOjSKtw84SIu2SDkdB9KTS+RpOHLr5masKySs+tGSFlY7bcEnPPAGOv1q219JdkyFbeNIlwgLBSijoPr3q152nXGmkuoa7/ANWw3E4fPyn2GPSsuwivIftVq8Mahkx5jpuBGeo7HvWqaer3Q4803zdSxFFBhpZIRIEG/cBw3pVy1865gincSRGQFliiwCF7MT/nrVeZf+Ja1tbsXygwY/4R6fzrThuY7m7kmRHSL7M0RDDDRNxjjv0qJt2uXUm0kinfpJDpU7XMjiFGCYcYZNxwCD3Geoq9YtBthkjTbEVEYBOQhAHGaNXvbWe3m84EwiP5QRy7gqVAHfLCqVlFJFBFGA+VUI6A/ePuOn41KvKOuhlFSl0L19uuJ4omOIoW8zP09aihl0uy1iHUZtS8oEHMG07ix6k47d6q3EFyUMb3Hlq7AMBwcc/rUQ0u2+0LKDKWUlELgE/qOaajG1m/uHKi2rHpEbrJGrxsGRgCCOQR606q2mkHT7cBi2EC5YYJwO4qzXmNWZ5rVtAooopCCiiigAooooAKKKKACiiigAoprZzxTqQBRRRTAKKKKACkNKfpSH6UgGmm04000ANNNbHvSnj1ph96AEJpKKQ0AFFJx60UAZqYqdenaoVFSqB6VRBOmMdKkA4qJAPSpRSAcB9aeo96YtSLQxjhx3pwB9aQU5aQC4JGDgg1mtpa21i1tpiQwwsWZoWXKNnqB6c1qDNKKabRSdjhNF0LVriFzfr9jIY5hDBkc+ox29jWfd2X2WUR31tjeCCWPzEdMjrXplcx4oL/AG6CNUy8i4Rhzj6iuunXlKWp24fES5rM5iTb5cqWsUkzwkI0iKCQSOeex+tR29tc30sbajc3EFrn5ra3AYjnqz9/oPzNS6GYjC6yBgwldZRjgvnIP5cfhW5PvjhW3tgB57BXYgEIvUsfbGa6ZS5dDec9OVGP/Zcltdyx6bPcXFs0QYRSsCVyMn0+XH1qHTbo6pKCskNsP4NzYOOnc8VrlRJFviO2YsCCRyo6Y/LjFcVZrdyzSrFGI4Ij9nM8pwrEHJJ9Oo+taU/fT5nqEOZRvc2zZ3UTi5e3WRFJZ5opN+AOvPbp61Yg1K3kZ2WdCVwSFb5iPpWLYTw3ssaS36Wv2hiHABzH6kjgD61Nr9lpUKhdMukinVzhWm3eYBnJLY69DjPt2q3FOSjLf0LVaUXZlu8v4hqVtA0q+ZICSD94gck+uPethHidA/nbowN+Se+K5O702SPUInLQEmFZRcgbiqt2Qnr656D8a6NLj+zLGz+1Wtz5MreWilNzyMBnnuOh5PFZ1IxSXLqaurzJM0k1K5tLcTpPaw2fm+XOzgl489GI/IY9810mkS7rZomlkne3bynlkABcgA54+orznT9NeCO8vdWXa99K0pWM/LGp4CnruPAz710Vjqxt1D2ZkuEKhmjwG8z5QMgjkHjvXNVo3Xunn1qN3eJ2VFYFp4gadQPshD5+YF8YH44rbgmSZNyMD6gHpXHKEo7nNKnKHxIkoooqSAooooAKKKKACiiigAxRRRQAUUUUAFFFBoAKQ/Wl/CmkUgGke9IfrTj7U0igBuPemEe9PYD3qM0AJzSH60ce9IeexoAMe9FJxRQBnrUqciolK96lUj15qiCVOtSjrUK4IIzUin3pASrUi1EtSL9aBjxTxTFNPXpSBDhSikFKKBi1U1GyS8gI+VZl5jkIyVNW6Kadik7ao8z1C1utHu5dkJmjcjzEXg5/hZT39KZJrMSyPI9gxJXaJJJwpVecgDGM8c/lWx4kstQuvFFtbyJJPYXAPltHwIcLht35gj3qzpXgyxsbVxqU32zDb97/AC4XHQ89O/avSVWCgnPfyO72sLJy3Zx2o+Kbazt5HYykxcbEUM27+7x3rHW8uryyuJbnlzIGSFASu5ux9G2nk1oa0V1WWd1WEWQnMNusKBSqnHzH178/SiC0UWNo9uBHfteLG8AHyrhSM89ASTznuBXdDkjFO2pupKybRkt4YlkhLLPt43AFf4vQn+tNt/D8u0SXF429WDARrwCDwuCfrXd3OnX6RfNZjCDDNu+9xk4z161UijluLZJI4ShY4ZGHI46YPQ1P1qcle/5HRGdKezKlhNJFZG3lgb7RDO0lu4OYwhOdvPTGB+XvV+W+vNW+yXNxGLN1VkFsQHPu6t7j+VZupWs82nmUNLFZmfy93DOw9OOOO5//AF0nhrUbO4kKRuomkcgb48rnHO1unOM8Vm4ppzS1MuSCfNF7GrPsXME08shcnyeAS3I9PukDmtK3gjWQSyXqzC3j2oITgkYzy3qPpVOSQtZ2/mXKyBS24FApTAxj/wDXUc0TS2rRrYtEpCxjGRvPUHPvj+VYtXRMrvVsniuxcKiW0V1cFf4vL9e2e/FWLY3Ol3cU80E8cXVQrbgQx5Vh2qPwzqjfYrm1hE8ckGB5ZUE4Y/fBHUAZq/qM4kubC0WaXLlpZWznaAP/AK3WondScLaGDm9Y20NrStatNReSKN9lzGcPE4IYe/PUVp155Zy3V/qVmYmWVolDfvBjb/dPHf8AwroX8QfZL0W95sZzkfuSW249eK56lBp2iYVMO4u0ToqKajK6K6nKsMgjuKdXMcwUUUUAFFFFABRRRQAUUUUAFFFFACZpCR706mnPtSAQkU04pxppoAaSKa2PWnmmMPagBpptONNIoATHvRS4ooAzVqRRTF+lSiqIHAdjg1IBgdPypq1ItIBV+lSDjoP1pgqRaAHDp0qQE0wU4c+1IY/NKM0AUtAxaMc570UUDCvM/F0+tjUb+zuneLS3YPFOMhAD/CTjnntXplNkjSVGSRQyMMFSMgitqNX2Uua1zSnPkle1zznS4oIpUTJVUTMZVA25hjj/AOtVTV4v7UlNy7hblh8yBflYj1HTt+ldPqXhmCAWz2MMkkEbfvYFkO5xg4IJPUHt3rDCbXjhn2rOmPOYtlg3Tn3xxXfTqqT5ovU9GFWNR3Rl2cBa2ZJ57p5FIVFRzsQ55BH+FWbrfa2l4kUk8TgGRyU2mEn+I98ZrYM8WTLaMiS2zE8rkMfp69OahvrDUblp7pogkyDfnzNm4DoMd8e9V7S797RDU0nra3mZz31nMY01a8mtZntwxkKg5c/KxUDu3/165e50e0RprTTJLy6Xy1Yyqny5UggAk5B69RXbRJHqAsVuoo0gkcOzgAHBHXPatbW7XTLK3W2sYoxdzfLEiuSSSCR9M4P61Ua/snaN7v7he7Tkt9TlZDHfWj20ayJKsv35Pu8EHHHPv+JrSN1cyyKLCzWIqPLOydnDL0OQB+XpTD4f1OScG4ntoEDAssOWIAPTJ45qnbQnUNdk8pxBaJvztbaFUcAAjqc5Oad4yWj2NJunPVa2HvJtuEhjmkiZFURlAQzknkAj096sfZ0uALiCa4MxwS7NuLjHAxjn/wDXVSWOOa3QsPN+U4kkbC5zgEY9fepEimFp/oUTTDGI41xwe/IP6UNmrhC/MPtFa3AurSdoZig3h1wGIJHTqe4OKmubhBK9zYO0Uy/vJoXXkdmK46j2qjGCttvlVJZmbhA/7yPA9PTOTmnloooMhWeQMfuScgEfNzSau7mUouWqNG11g2gjWyu7mSLHLTIFX2Cj8+tdFpHiKK6k8q6aONz90qchq5G2xeyCOx3yFVC+WDkBh3JPQcU3UrW9swXmjZ4iv+vhwAWOfvHqfyrKVKE/dejMZ0qb0lv+J6cjq6hkYMp7g5p1ed6XqUum3EfybpNhQoxwCQNxJ98V1HhzWJNR8yK6SJZ05zE2VZfX1FcVSi4a9DiqUJQ13RuUUUViYhRTd679u4buuM806gAooooAKKKQ0gAmmk0HNIetACE+tITQfpTfwP1oAQn3puaU5H/6qQ/j+VADaQ0p+lNP0/SgBMe5opf89KKAKK5x2p65qNOnWpVBqiSRc09c5zTVFPFIQ8E+lOXNNFOHFAx4PtT1popwpCQ8U6minUFC0UUUxhRRRQAVl6po1teObhYYxeKMLI2ce24DrWpRTUnF3Q02ndHGf2FciG6aYO/zgAsqhnGOTgHp6VXti9yV02a98u2ZSHYgbiv93cfXpXd1zM/hoyF1MkckYkaVC4O/n+HdnpXTCtf4zqjiOdcszmlgEZligA+z7isTO27agyAoH61Ztb+e1ttlta2pkfrc42/QYHtUOp5srmO1uE8suOZHyQg6DoCeaijaSK0kmNwBErBGjU5klGOgBHTv+FdluZanY1Bq242Vp3dpNQupJmHSMDABB7Ae9VLiCOZGdlKMylihYqT9R/jTxETJIhiZkAAy54x2wfTj86q3TRm4vJDDLMowwVCQAeOSO/4nFaRWuh0xlCKtYt2g07Ubn+zb67MdkYM9dquc8orDoMVZu4dNsoGXTbqeO3i2qrMcoQB0Q9QB6niuYhtJMBrYCG4c7yjPkSk8HGDwMVNvujFa2X2iKPzYd/yxkheTkHPfpwaqVL3tHoV7LVTUvkO0p57iFtzgCdmkkXIMcTZ+XkHkkZyAfart07KsRtlCyKpEijpnttHOeB3rMmxDE0Vnc29tIHCxIirlpeu0Ducde1SxWV7vjlbWI5JEOAFiOwf7JwDg9enHNaWTd7g4xjI0LqITJG4zAx2J+7AVm55+pp1xFCLlnltp/JJ+6GHmZA6/KPpwKyGvELr9oK3EqttRVzkcDGM9q0mMqWqkKsSSc5kyWQ9AgOeP/r1DTVgdNL4SxbtIySeUm6EER52gdemfxx1/MU+0d0vJkd1j+Qbi7tkMDgYC4PH1qi0qsyzCT/R+Q0YHV+m7B+mKftWS02iDY0q7i4ckoAR2HuMVPLcicXG6kdbB4lu40YbYrkL93afmYe3rWidfkdVj8gwzOjE7j904JFcm+rnStQuLiz043phjXEedhPH8JPy549c8ipG1W21XVBdRRi3vGAJhZ8lgAQenXjj6YNcjoJ6qOhxujGT+H+vQ0omkDIJHO8uWEuSTk11WizT3GmwyXQAmIOcd+eD+Iri5L5y2IIZVlGQA5AXP1/WtCPxYtpGIbpQGG3DD0I9O5z2rOpSlJe6jGtScvhR17yIoYkj5RkjvSxuJI1dc4YZGa5qz8R2bv5tzA0Ikx+8ZMBgenvWvYataXsnlwvh8Bgp4JBz0/KuaVOUd0c0qU4q7RoUU3em/ZuG7rjPNKfpWZmGfakJ5oJ9qbQAE0hNIcelNIHpQAE9qYxP40p+lNOBQAE0hopOKADJ96KMD/JooAz1JHapVJ9KhU1MpqiCVenSnimKaeDSAcDTwaaKcOaBjgwxTww4popw+lIQ8GnA0xfpTxQUOzRSClpjCiiigAooooAKKKKAM3UdJhvbu2uSdk0JJyBneMEbW9Rk5/CuFvdNmbVpElnjQO2GkkQjnbg+3bIx616ZVC/0u3vI5A0aq8mNzgckDt9O1dFGu6b1N6VXk0Z53KqRlI1jlMD/IsjADeVxzj0BqeezuYrD/AImV1HZ2yDECIdzyse5A69e/p0rWu9KkS8eAv5YCllPUEE9B6deetZd8Zp0SdViYxN8rKuMdOvtXap81rHcpc1rM5poJrtbiGExbol3qs67c9O3v1xxToUks7VW+zOZJ9v8Ao4YELgfOCf8AZOcHuDXRa1cx3k9nPBbbGDlLoL8rbuGA+nB59DWd9nZbazs/K3tI/wC7cZ3cnoc9ORXQqja1OiNRuz2/r+mc5DHbW9tc6jgRx7mmkEp3HzBwFXHTjqah0q7misIrTT4nmuLj52Rjuyx5YewAODXQRwr9juFnDRW7ExzOMAKeuQpHOcAf4YpNOVBNcT6YYLeeJMLbO+47RyVHoT+fFa+03ube2LlpommwGZJTKskVqZvLZWHOeoz29657VZY9QdtOlkLRABooxwzy7gefQDr9M1pPqd1LPB58ka3AthGA5OX+Y5U/gB+dZS2yzTteKFjiUMOwPJ57HOOfwFKCad5PUUFJxfMaVrJLLZRqsAVX3IrnH70d/oPpVmFCXjZJdtuqgMCgzhckL9Oc55rOtIZBbwN9sD4GFiIKhDnqT0ycD8q1dPaFyyXEqPGMMwAyc9M9enr6cVE7LVESScrTKNjBe3GrxQWltD5EqO9zGCQx5AAQH73Xn0Ap9tokq3aSNPNHFG2+K3bBEbcjHIzyCeK7bwvNBNqCRmOIty6kDJU46g07xJaxW2rIVO0XALlSeCQecfmK53iGp8lraGPtbTdJoyZQqxMJsAk5OD909ufzqrGwNzHNcBJNvKuMnA96fJcRPJsTliSCwHA44rGvLmQ3rRxn5NuCDgKoPVmB5AG01UY3OhJRVpEU1yftAjnu4gZiWj3ZDE5PABJ4xx7U23nKXKyRORKwISQMVYLx/wDWzWTPdWu5m+zGSSO4keC6L5cpwUUY4xjnpxnHY1dSK4uGVbdFMbAneGwEyw/XrXQ4JLUISbXl5mhNrt+Xn8zUpllC/K8XDkHseOnHapbXxNqaLK8moXJ6bCFDALjjPvn65rn7+GSzkLTQhnL/ACsM8L6k9+ePxqzDOGZPJhLMYySARgg8k59fp25qXThbYn2dNr3kd3onjtJHI1FcW3AWdVIO70K/56V2Njf2t+jNaSiRV6kdq8NklQMZBuWMnAYEBUbGOfw5zWvoet3Gj3EMgL+SP3eyRyFUE9cdDk9/yxXHWwcXrA46mDUr+zPZKbkVj+Hteg1q3DouxwM4zkN7j1rXyK82UXF2Z50ouLsxD35ppp2RimnFIkQ01hxweaUmkJoAXiim0UAUFx7VKpzUK49BUigelUQTKaeDUa1IKQDgee2KlHWoxT196BjxThSClFJCHilFNFOFModS0lApALRRRTGFFFFABRRRQAUUUUAU9S0+HUIRHNuUqcqy4yp9q5gaBex3M0IDG2Y580SABgOgZf8ACuzorSFWUFZGkKsoaI86ubZ4sgRPJI0ocyYLEgAjj65/SmxNcXEbtbBj5MbgvgZTdnLZPQ44z7mux1LRxdNIYZzCJQFlUKCHHpngj8DWVrFjJZaaIUntrOzOd6xxsTIT1GeSBiuqNZSsup1xxEZWVtTlru11GZobZLKVlklLKz8K2cZOfSqwRItZeO9ikeIoyFowFMhTaRkn69a1XW+j0+KeGaWa0ZiInUjjA65PK+nPpWRfstxcx3EYlMw/clQcgOeeenOeRiuuMnLTodUeaWt18jJMlxaNKZ4WErzMzpwwK8KoHp3ORUF1aXyyo0IXy5SVCGTDdOSR/F1roTbLDeOLWVAI0Ehbo8jbsHIJ4waWayhubjlvKnjO5yX4OSwx7dRn6Vr7W2prHEWi+ZblC4hDTg2w3xBSAmzA+YbWxnIxjnJH0NT2sD/bZVulljuOCDIo+demR3weDinsJIRJDctHk+WrMoKKoAJIJ9fp1IqSC0VJQwnjuHmTqZfMZBj7pPbr0qG7KxEJJyR0nhmNIdehjXdzE8gwcDHHUd+tJ401Bn1OO0VE2RA5Y9dxAPHPpWj4Jt4oNFS4kkLuieSzNj5VQnv9MVy+oXAvNSmmmJZTIX2RuFk29ApJzxgexrjguaq32MIN1K7m1sU0jaM7kciXIZSDg8dawtVFxdT3cj+W13cNmQtziM8AE45AHGBjnmrs27YsW+TcigM4O4jk9z1x0zSlRHCQquucHIbj6/jXdFcrud1RqTv1KDWxCwFmRXXBUuP/AB3Hoa2tEwLJw4wdxDDtn1/rVGNFZVaJ92MEAjKqfYe2abAZIJGdLgx8YdHBfk9CAOMk8Yol7ysLmtuVfFknnPZQR4Vt7v3+5gA/TJ9fwqha2yPZKQUhuE2kLI/zEY6D6DFdBALJ9Rb7egmzHuV5OcNgZH8+D0rDvPm81Y1UL5m8kD5lUgjr7+lXCWiiKMnexJcMbiFYII9xdS3mou7cSMdOvTP51VidYordZJ5fLkhKyRsm3YR0IPcZA4pbmJBcxJEm2YKrb5QRGB0zt6+n51edLYyMsro8SnzBOhOE4ICgH1PU03ZITkpbEehaztuzJFcTQtCC64XZ5i9MjI5GeteqeF/EsWq2yLMRHddCpGN3vXkFtZ2dpfNcxxb5NhjViWbAbjavp1J545rQtzLDdLBCmxQu4uG+cdwMd65sRQhV1WhFbD+1Xvbnt7HFNJ96890bxdqIcpfKlwh+YPFwRk9Dnpiukh8TWslwsW04Pfv+IrzJ4ecXY8qWGqR6G4Sc+tITUdvcxXMYeFwyn0qU1iYtNaMM0UUUCM5alWoBnP3uPpUibvVTVEk6+ualUg1CmakXPpQIkB7inrUYJ9KcDSGSrThUYNPz6UASA04GogacDQBIPxpaaDSikMcKKSloGFFFFMAooooAKKKKACiiigApssayoySAMpGCKdRQBC1rA1obZokNuV2eXjjHpiub1fwlbzQFdOiihO7cQSwJPHOex4BzXVUVcKkoO8WXCpKDvFnAx2lvYQR2Vxpz28wbatwRu80+rHpk8msmBILe6Mvlb1Z2LlcksCwyM4yABk8+gr1QgMCDyDWPe6FbyIn2ER2kqcBljBG09QRXRDE783U3jiL6SOGe2aS0DGUMZpzG4HBMfUZ9+P1qtp1p5QtkyhkferxhNvl7SdpP1HFdrN4YCgm1nO7O4eZ6/UdqpXPhW9mcSfa4hIDn+LBwOAa3jiItWudEcRC90x3htVvdL1TT0kKSOxdSRjG5QMj2yP1rnbrRrpWLS2M8kkSnCxSBSWyBuJPBA569a7XTPD62V4l4JyZ8EMMZGD1A/HvW4yhgQwBB6g1zvEckm4bMxniOWUuTZnkmp2T2RUTb2Mo8xDkFGU+hx6flVECNvNdIkxv8skEkNnoD9BmvWdY0mDUrQxOBG4UrHIo5T6Vyi+CriO4t/wDSIpIl4fgpnA+U4HU10U8VFx97c2p4u6956nLTxSW8lusiMHK/KCmNwPUjv6d6ie3iNuyTB5mcAckLkZ5OD1x/Sutm8LX6yH5hcRxpiMb9vXt/nFR6p4Uurezt5LCM3FwGHmICPujnAJI7gCrWIhtcp14K2qOVNrGssjM7NG0u7HPykjkjvn9KgcRMqeVIvnyhmwyEBMYwScc10upaVLEoV42QjDPvIzk84z04PpXOyOTeLaqgCMnmEKdwJyRj61rCfOrotSTd0zNjuGmEjTxOZGAEhLBi+ODycdew9qlmtrYWcUCxPHIjl5n8w4lyQVx6ccGtK3tWhQsy+dHbPk78EAMcANnnGap6xYRSOIkPmNA6qRHIQ0ZPP48DI+hq1NXNOa2nUhto0gtESeMOsTcYc5Vu31GD3qe0wrTEXARkxyfvoeeD6VDp9pI63KsRG7nBVfTBAPJ9jxzWhLbQxxokcPATmTGWlbdkFvQ1M5K9jSD1vBFYJN5lw9xNuDqF2D7ue5B60+ORbYhiMyEBPkY4Hof8+ta9jo80um+commiVyMquW68ge34UXVlcRBAtr5aMpUkrjH1PSsXUi3Yl1op2juO8Nay2nzt5mGjcHcrHn2x713entM8JkndX3ksmOy9q870fR7jVNQVDkwrzJKFygI4xz+WK9NijWGFI1yVRQoz7VxYnl5tDzsXKLldbsdn3opMj0ormOMz1NPFRrzUir9aokkXkjJNTL9aiVfrT1FAiUH3pwz60xRTwKQxwzUgpiinjOaAHLTxTQacDQA4UoPsaQU4UDAUvNFLmkACiiigYUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADTTTqQkUgKt7Z219D5V3CksfowrA1Hwbpt0h2J5D9VZOuexPqR2NdPSVUako/CyozlHZnEf8IZKJ5sXY2PyHOckjkbh35qrb+CLiK5lbz4VDY/edXz34AAFegGmmtPrFTuae3mciPBlrIjPPJJ9pQMsDqxxFnvjvzzg9CTWpYaJbw2sK3Uccs6AbnC4DN3OK2D7004qJVZy3ZLqzfUYqhFCooVR0AHFI3zKQwyD2Ip5NNNQZkSRpEu2KNUXOcKuBmgmnk00n60ANopc/WigDPBqRSRUS09etUSSqfepVJqEZ54qQH6fnQIlVjTkJZQcYz2NRg+gqQHPY0hjwTTwajB56U8H2oAeGpwNMBpwNAx4NOB7UwH6U4E47UAPpaYDz1FOzQAtLTc+1Ln2pALRRRTGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFJmkAtIaTPvRn3oAXNNJozSUAFITRSc57UAJScUY54NMNACk00mg0n4UAFNJoOfSmnPJx+tACE0w0k0giQu/AFAOQD2I45oAXFFJz/AJNFAGeufWpBUSk+lPWrJJlx3qQYqEZqRSaQEy09eaiGaevWgCUU4VGtPz70gJAaVSfWmA04UDJAacKYD70uRQA4/hS/hSce1KKAHClpAaWgAozSGgUgHUUUUxhRRRQAUUUUAFFFFABRRRQAUUUUAFFGaQmkAGkOaCaQmgA5pKM0hNAAetJRSE0AIc9qafrQTSZoASkpTTTQAhpppxphzQA11VhhuR70mKDTTQAvFFJ+NFAGYueualGaKKsGOFPXNFFIViRefWpAKKKAJBxTxRRQMcKdRRSAcKeDz0oooAdS0UUALmlzRRQAGiiigBwpc0UUAGaKKKACiiigAooooAKKKKACg0UUgGmkxRRQAhoxRRTGJSGiigQU00UVIxpptFFMBKSiimIaaaaKKQxh96YaKKADNFFFMD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of an hematoxylin and eosin-stained prostate core biopsy. The majority of this core is involved with malignancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_4_15439=[""].join("\n");
var outline_f15_4_15439=null;
